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Atopic dermatitis (AD) is a chronic skin disease, which affects 10 – 20% of children 
and 1-3% of adults around the world. AD is caused by skin barrier dysfunction and immune 
system dysregulation. Current treatments for AD using corticosteroids and 
immunosuppressants to suppress inflammation could have serious side effects. Hence, there 
is an urgent need to study the pathophysiology of AD and discover better treatments for AD 
through the recovery of the skin barriers, and inhibit inflammation, which aggravates AD. In 
this project, we choose to study antimicrobial dermcidin (Project 1) which is related to skin 
barrier dysfunction and NF-κB (Project 2), which is partially responsible for immune system 
dysregulation. 
Project 1:  
The human antimicrobial peptide dermcidin (DCD) kills a broad spectrum of 
microorganisms and is highly related to atopic dermatitis. In sweat, DCD peptide is 
proteolytically processed into fourteen DCD peptides. In this study, three DCD isoform-1 
peptides (DCD1L, SSL29, and SSL25) and one DCD isoform-2 (DCD2) peptide were 
chosen for functional and structural studies as they have distinct isoelectric points (pI) and 
net charges. We determined the 3-D structures of DCD1L, SSL29, SSL25 and DCD2 in the 
membrane-mimicking environment using NMR spectroscopy and elucidated the 
membrane/DCD peptides interaction using biophysical methods.  The knowledge obtained 
from this study will help us in the understanding of mechanisms of the antimicrobial 




NF-κB is a transcription factor that controls over 500 genes and plays a key role in 
the regulation of the human's immune system. The dysregulation of NF-κB is associated 
with many human diseases including atopic dermatitis and asthma. In this study, we 
elucidated the interaction of two of the most dominant NF-κBs (P50 and P65), with their 
small inhibitors, andrographolide and parthenolide. We mapped the binding site of 
andrographolide on P50 and determined the interaction efficacy of andrographolide and its 
derivatives with P50. The interaction efficacy of helenaline and parthenolide with P65 was 
also determined. We reported for the first time that parthenolide can interact with P50 
through Cys62 and inhibit P50/DNA interaction. Our study will help to design better drugs 
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CHAPTER 1.    INTRODUCTION 
1.1    Atopic dermatitis (AD) 
Atopic dermatitis (AD) is a chronic, highly pruritic, inflammatory skin disease 
that is characterized by relapsing eczema, intense prurigo and Staphylococcus aureus 
colonization.  AD is the most common chronic inflammatory skin disease, which 
affects 10 – 20% of children and 1-3% of adults in all parts of the world, especially in 
developed countries (Ong, Ohtake et al. 2002). The number of AD patients in 
developed countries has increased by two to three-folds over the past 3 decades 
(Leung and Bieber 2003; Olesen, Bang et al. 2005; Harris, Williams et al. 2007). 
1.1.1 The Burden of AD 
AD causes a high economic burden on AD patients and their families. 
Annually, the total cost of AD in the United States is between $US 0.9 and $US 3.8 
billion (Ellis, Drake et al., 2002). In Canada, AD also costs approximatly $US 1.4 
billion per year (Ellis, Drake et al. 2002; Barbeau and Lalonde 2006). Besides the 
economic burden, AD also causes significant physical burden for affected patients 
and their families as it impairs daily activities (school performance, participation in 
sports, and other social activities) (Fivenson, Arnold et al. 2002; Chamlin, Frieden et 
al. 2004). In summary, the rising incidence rates of AD, and the associated high 
economic cost and physical burden are having huge effects on health-care 




1.1.2 Pathobiology of AD 
The pathobiology of AD is complicated and results from complex interactions 
between the genetic and environmental mechanisms (Cork, Robinson et al. 2006). 
Emerging evidence suggests that AD is caused by both skin barrier dysfunction and 
immune system dysregulation (Leung and Bieber 2003; Spergel 2008). So far, the 
best model to explain AD pathobiology is the “outside-inside-outside” model (Figure 
1.1) proposed by Elias et al., 2008 (Elias, Hatano et al. 2008; Elias and Steinhoff 
2008). Briefly, dysfunction of the outside skin barrier allows chronic exposure to 
allergens and bacterial pathogens that lead to sustained expression of proinflammatory 
cytokines (inside), which generates further insults to the outside barrier.  
 
 
Figure 1.1 The “Outside-inside-outside” model of AD. 
The model shows the importance of both the skin barrier (including antimicrobial 
peptides) and the inflammation responses in the progression of AD (modified from 






Skin barrier dysfunction 
The skin barrier consists of a permeability barrier and a chemical barrier. The 
permeability barrier is formed by the stratum corneum and the extracellular lipid 
lamellae matrix (Elias and Menon 1991; Elias, Hatano et al. 2008). The chemical 
barrier consists of secreted antimicrobial peptides (human beta-defensin, dermcidin, 
cathelicidine, etc.) which help to resist microbial pathogen colonization. The 
breakdown of the skin barriers including the permeability and the chemical barriers is 
responsible for the onset and development of AD. In healthy skins, the stratum 
corneum serves as a barrier protecting from the penetration of irritants, allergens, and 
microbes.  The stratum corneum of patients with AD is thinner and more susceptible 
to damage (Imokawa, Abe et al. 1991; Spergel 2008). Loss of functional mutations in 
the filaggrin gene, a key protein for the formation of the skin barrier, results in the 
development of AD. Stratum corneum flattening and decreased stratum corneum 
hydration caused by fillagrin null mutations and lipid lamellae matrix alterations 
enhance antigen penetration (Elias and Menon 1991; Elias, Hatano et al. 2008). In AD 
patients, not only is the permeability barrier weakened, the chemical barrier is also 
deteriorated. The function and expression levels of important AMPs including 
defensins, cathelicidins, and dermcidin are significantly reduced in the skins of AD 
patients compared to the expectation when normal skin is injured (Hoeger 2004; 
Melnik 2006; Hata and Gallo 2008). As expression levels of antimicriobial peptides 
are significantly reduced, microbial pathogens, especially Staphylococcus aureus 
rapidly grow and colonise the weakened-skin-barrier area (Hoeger 2004; Tang, Wang 





Immune system dysregulation 
As the skin barrier is weakened, antigens penetrating a defective barrier or produced 
by colonized microbial pathogen exacerbate AD by inducing the production of 
inflammatory responses. These responses further disrupt the skin barrier and complete 
a potential "outside-inside-outside" pathogenic loop (Elias and Menon 1991; Vickery 
2007; Elias, Hatano et al. 2008). NF-κB proteins are ubiquitously expressed 
proinflammatory transcription factors (Gupta, Sundaram et al. 2010) which play a 
central role in the immune system response as well as inflammation. Many genes 
involved in inflammatory diseases, such as IL-9, IL-13, eotaxin, TSLP, ICAM-1, 
VCAM-1, E-selectin, etc, are known to be regulated by NF-κB as they contain κB 
sites within their promoters (Ahn and Aggarwal, 2005).  
Numerous NF-κB inhibitors, such as IKKβ inhibitors, IκB degradation 
inhibitors, NF-κB-specific decoy oligonucleotide and p65-specific antisense 
oligonucleotide have shown positive effects in inflammatory diseases. (Birrell et al., 
2005; Desmet et al., 2004; Ziegelbauer et al., 2005). The positive effects suggest that 
the inhibition of NF-κB pathways is a promising strategy for the treatment of 
inflammatory diseases. 
1.1.3 Current treatments of AD 
The treatment for AD is complex as it is based on the severity of the disease 
and requires a combination of different approaches involving the use of topical and 
systemic drugs. Current effective treatments for AD and other inflammatory diseases 
mainly involve the use of corticosteroids and immunosuppressant to suppress 
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inflammation, which could have serious side effects (Vasil'eva 1968; Ziemssen, Bauer 
et al. 2009). The use of chemical antibiotics for AD treatment is limited due to the 
development of resistance in many of the pathogenic bacteria. 
1.2    Scope of this project  
The rising incidences and high economic and physical burdens of AD are 
having huge effects on health-care systems worldwide. Hence, there is an urgent 
need to study the pathophysiology of AD, discover better treatments for AD 
through recovery of the skin barriers, and inhibition of the inflammation which 
aggrevates AD. In this project, we choose to study the antimicrobial dermcidin 
(Project 1) which is related to the chemical barrier dysfunction and the interaction of 
small molecule inhibitors with NF-κB (Project 2), which is partially responsible for 
immune system dysregulation. 
Project 1: Functional and structrural studies of the human antimicrobial peptide       
dermcidin 
The antimicrobial peptide dermcidin is constitutively expressed in sweat 
glands as a chemical skin barrier but found to be significantly suppressed in the case 
of AD. In this study, we aim to study the structure and biophysical properties of 
dermcidin (DCD) antimicrobial peptide. Structural information obtained will enable 
the elucidation of the antimicrobial mechanism, which will help to design better 
treatment for the AD patients.  
Project 2: The interaction of NF-B (p50 and p65) with their small inhibitors 
andrographolide & parthenolide 
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NF-κB is the central regulator of immume systems. It regulates the expression 
of many imflammatory genes, which are responsible for the initiation, and 
development of AD.  Therefore, in this study, we focus on studying the interaction 
between NF-κB proteins p50 and p65 with their inhibitors in order to find out the 
mechanism of action.  The findings will aid in the design of potent drugs with higher 
specificity and lower cytotoxicity to combat inflammatory diseases including AD.    
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CHAPTER 2.    MATERIALS AND METHODS 
2.1    Materials 




 Base, Avanti, Bio-Rad, Sigma-Aldrich,  




C) AppliChem, Cambridge Isotope 
Laboratories, Novagen,   
DNA polymerase and restriction enzymes Fermentas, Merck,  New England, Promega,  
Gene synthesis and oligonucleotide primers 1
st
 Base, GeneScript 
 
2.2    DNA cloning 
2.2.1        DNA insert and polymerase chain reaction 
The desired DNA insert was systhesized by polymerase chain reaction (PCR), 
using the forward primer containing the BamH I restriction site and reverse primer 
containing the TAA stop codon and EcoR I restriction site. 50 μl of PCR reaction mix 
contained 5 µl of 10 x KOD Hot Start buffer, 3 µl of MgSO4 (25 mM), 5 µl of dNTPs 
(2 mM each), 2 µl of DNA template (150 ng/µl), 3 µl of each primer (10 µM), 1 µl of 
KOD Hot Start polymerase (Novagen) and 28 µl of ddH2O. 25 PCR cycles were 
carried out with 1 minute denaturation at 96
o
C and 1 minute elongation at 70
o
C. The 
annealing temperature was adjusted based on the melting temperature (Tm) of the 
primers used. A 1% agarose gel was used to analyze the PCR's product quality. The 
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DNA band with the correct size was cut and purified using the Gel Extraction Kit 
(QIAGEN) according to the standard manufacturer’s protocol. 
2.2.2        Subcloning 
5-10 μl of purified DNA insert (about 100 ng/μl) was digested in a 1.5 ml 
ependorf tube using 1 μl (10 U) of BamHI FastDigestTM, 1.5 μl (10 U) of EcoRI 
FastDigest
TM 
(Fermentas), and 4 μl of 10x Fast Digest TM buffer with a total reaction 
volume of 40 μl. 3 μl of plasmid vector (about 150 ng/μl) was digested in a separate 
1.5 ml eppendorf tube using 1 μl (10 U) of BamHI FastDigestTM, 1 μl (15 U) of EcoRI 
FastDigest
TM 
, and 2 μl of 10x Fast Digest TM buffer in a total reaction volume of 40 
μl. Both of the digestion reactions were carried out at 37°C for 2 hours. 
The digested DNA insert and plasmid vector were mixed and purified using 
QIAGEN spin columns.  The purified digested DNA insert and plasmid vector were 
then ligased using 2 μl of T4 DNA ligase enzyme, 2 μl of 10x T4 ligase buffer in a 
total reaction volume of 20 μl. The ligation reaction was incubated at room 
temperature for 2 hours. The ligated plasmids were then transformed into DH5-α 
competent cells.  
2.2.3        Preparation of E.coli competence cells 
The E.coli strains (DH5α or BL21(DE3)) from the -80oC glycerol stocks were 
streaked onto a plain LB agar plate and incubated in an incubator overnight at 37°C. 
A single colony was picked and inoculated into 10 ml of LB media overnight at 37°C.  
100 µl of overnight culture was transferred into 100 ml of LB media and incubated at 
37°C until O.D600 reached 0.4.  The culture was centrifuged at 3,500 rpm for 10 
minutes at 4°C and the supernatant was carefully discarded.  The cell pellets were 
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gently resuspended with 40 ml of pre-chilled glycerol buffer (0.1 M CaCl2, 15% 
glycerol) before being incubated on ice for 30 minutes. The cells were then 
centrifuged at 3,500 rpm for 10 minutes at 4°C and the supernatant was carefully 
discarded. The pellet was gently resuspended in a 4 ml of pre-chilled glycerol buffer 
and incubated on ice for 2 hours before being aliquoted at 50 μl per tube. The aliquots 
were stored at -80°C. 
2.2.4        Transformation of plasmid DNA into E.coli cells 
20 μl of ligation mixture, which was obtained from the subcloning step, or 0.5 
μl of intact plasmid (150 ng/μl) was added into a 1.5 ml eppendorf tube containing 50 
μl of DH5-α competent cells and kept on ice for 20 minutes. The heat shock 
transformation process was performed by quick transference of the eppendorf tube 
from the icebox to a 42
o
C water bath and incubated for exactly 90 seconds. Next, the 
eppendorf tube was incubated on ice for 2 minutes. Following that, the mixture was 
added with 1 ml of LB prior to incubation in a 37 °C shaker for one hour. The cells 
were harvested by centrifuging at 6,000 rpm for 2 minutes. The supernatant was 
gently removed and the cell pellet was resuspended with the remaining 70 μl LB 
broth. The cells were then plated onto the LB agar/ampicillin. The plate was 
incubated in a 37°C incubator for 16 hours. 
2.2.5        Colony PCR screening 
In order to screen the colony containing the plasmid with the desired DNA 
insert, at least 5 colonies obtained from each subcloning plate were verified by PCR 
screening. The colony was labeled and then half-picked by using a sterile pipette tip 
and boiled for 5 minutes in a 100 μl of sterile water. The sample was subsequently 
centrifuged at 13,000 rpm for a minute. 1 μl of the supernatant was used as the DNA 
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template for the PCR reaction. 50 μl of PCR mixture containing 1 X Taq reaction 
buffer (50 mM of KCl, 10 mM of Tris-Cl with pH 9.0, 1% Triton X-100), 0.75 mM of 
MgCl2, 140 μM  of dNTP, 0.5 μM of forward primer, 0.5 μM of reverse primer, and 
1.5 U of Taq DNA Polymerase (Promega) was prepared. The PCR reaction was run 
with 30 cycles, with each cycle involving 1 minute of denaturation at 94 °C, 1 minute 
of annealing at 52 °C and 1 minute of elongation at 72 °C. The colony that had the 
PCR product of the correct size was selected for the plasmid extraction and the DNA 
sequencing confirmation. 
2.2.6        Plasmid extraction 
Selected colonies with the correct PCR results were picked and transferred to a 
15 ml falcon tube containing 10 ml of LB broth with a 100 μg/ml of ampicillin. The 
falcon tube was then incubated overnight in a 37°C shaking incubator. 5 ml of the 
overnight culture was used for the plasmid extraction using a QIAGEN Miniprep Kit 
(QIAGEN). The extracted plasmid was eluted with 40 μl of sterile distilled water. The 
concentration and purity of the extracted plasmid was analysed by using a NanoDrop 
spectrometer (Thermo Sciencetific) and stored at -20
o
C. 
2.2.7        DNA sequencing 
The amount of plasmid template used for the DNA sequencing was between 
250-500 ng. 2 μl of  the plasmid template (150 ng/μl) was added into the PCR tube 
containing 3 μl of sterile distilled water, 1 μl of sequencing primer (3.2 μM), 2 μl of 
5X Big Dye Buffer and 2 μl of Big Dye Terminator V3.1 (Applied Biosystems). The 
PCR reaction was run for 25 cycles, with each cycle involving 30 seconds of 
denaturation at 96 °C, 15 seconds of annealing at 50 °C and 2 minutes of elongation at 
60 °C.  The obtained PCR product was added into a mixture of 3 μl of 3M sodium 
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acetate, with a pH of 4.6, 62.5 μl of 95 % ethanol and 24.5 μl of sterile water.  The 
mixture was then incubated at room temperature for 15 minutes to precipitate the 
DNA. The precipitated DNA was harvested by centrifuging at 13,000 rpm for 20 
minutes at room temperature. The supernatant was gently poured away. The obtained 
DNA pellet was washed twice with 500 μl of 70% ethanol. For each wash, the sample 
was centrifuged for 5 minutes and the supernatant was gently discarded. The obtained 
DNA pellet was dried using a vacuum centrifuge before being sequenced by an 
automated sequencer, ABI PRISM 3100 (Applied Biosystems).  
2.2.8        Site-directed mutagenesis (SDM) 
Site-directed mutagenesis was performed using PCR-based site-directed 
mutagenesis (Figure 2.1). For each single mutant, a pair of complementary primers 
with the mismatched bases in the middle was designed. The PCR using the high 
fidelity KOD Hot Start DNA Polymerase (Novagen) synthesized the whole plasmid 
consisting of mismatched bases. The PCR reaction was performed using 50 µl of PCR 
mix containing 5 µl of 10x KOD Hot Start buffer, 3 µl of MgSO4 (25 mM), 5 µl of 
dNTPs (2 mM each), 2 µl of pET-M/p50 construct (150 ng/µl), 3 µl of each primer 
(10 µM), 1 µl of KOD Hot Start polymerase (Novagen) and 28 µl of ddH2O. Fifteen 
PCR cycles were carried out, where each cycle consisted of 1 minute of denaturation 
at 94
o
C, 30s of annealing at 45
o
C and 3 minutes of elongation at 70
o
C. The 
methylated wild-type plasmids were digested by adding 1 μl of 1U of Dpn1 
FastDigest
TM
 restriction enzyme at 37°C for 1 hour. The mutated plasmids were 
subsequently transformed into E. coli DH5α competent cells and plated onto LB agar 
with ampicillin at 37
o
C for at least 16 hours. The mutated plasmids were verified by 







Figure 2.1 Generation of Site-directed mutangenic plasmid by PCR-based method 








Table 2.2 List of primers used for p50 mutagenesis studies. 
 Mismatches on primers used to generate site-directed mutations to alanine residues 
were underlined. 
P50 R51A-Forward: 5' CAAATATTAGAGCAACCAAAACAGGCGGGATTTCGATTCCGC 3' 
P50 R51A Reverse: 5' GCGGAATCGAAATCCCGCCTGTTTTGGTTGCTCTAATATTTG 3' 
P50-R52A Forward: 5’ GAGCAACCAAAACAGGCGGGATTTCGATTCCGCTATGTG 3’ 
P50-R52A Reverse: 5’ CACATAGCGGAATCGAAATCCCGCCTGTTTTGGTTGCTC 3’ 
P50-R56A Forward: 5’ CAGAGGGGATTTCGATTCGCCTATGTGTGTGAAGGCCC 3’ 
P50-R56A Reverse: 5’ GGGCCTTCACACACATAGGCGAATCGAAATCCCCTCTG  3’ 
P50-R54A Forward: 5’ CAGAGGGGATTTGCATTCCGCTATGTGTGTGAAGGCCC 3’ 
P50-R54A Reverse: 5’ GGGCCTTCACACACATAGCGGAATGCAAATCCCCTCTG 3’ 
P50-V58A Forward: 5’ GGATTTCGATTCCGCTATGCGTGTGAAGGCCCATCACACG 3’ 
P50-V58A Reverse: 5’ CGTGTGATGGGCCTTCACACGCATAGCGGAATCGAAATCC 3’ 
P50-C59A Forward: 5’ GGATTTCGATTCCGCTATGTGGCGGAAGGCCCATCACACG 3’ 
P50-C59A-Reverse: 5’ CGTGTGATGGGCCTTCCGCCACATAGCGGAATCGAAATCC 3’ 
P50-S63A Forward: 5’ GCTATGTGTGTGAAGGCCCAGCACACGGAGGGCTTCCGGG 3’ 
P50-S63A Reverse: 5’ CCCGGAAGCCCTCCGTGTGCTGGGCCTTCACACACATAGC 3’ 
P50-V112A Forward: 5’ CTGCACGCCCACAGCCTGGCGGGCAAGCACTGTGAGGACG 3’ 
P50-V112A Reverse: 5’ CGTCCTCACAGTGCTTGCCCGCCAGGCTGTGGGCGTGCAG 3’ 
P50-N136A Forward: 5’ GACATGGTGGTTGGCTTTGCAGCCCTGGGAATACTTCATGTG 3’ 
14 
 
P50-N136A Reverse: 5’ CACATGAAGTATTCCCAGGGCTGCAAAGCCAACCACCATGTC 3’ 
P50-I139A Forward: 5’ GGCTTTGCAAACCTGGGAGCACTTCATGTGACTAAGAAAAAGG 3’ 
P50-I139A Reverse: 5’ CCTTTTTCTTAGTCACATGAAGTGCTCCCAGGTTTGCAAAGCC   3’ 
P50-L140A Forward: 5’ GGCTTTGCAAACCTGGGAATAGCTCATGTGACTAAGAAAAAGG 3’ 
P50-L140A Reverse: 5’ CCTTTTTCTTAGTCACATGAGCTATTCCCAGGTTTGCAAAGCC    3’ 
 
2.3    Protein expression and purification 
2.3.1       Protein expression 
The expression vector containing the desired DNA insert was transformed into 
BL21(DE3). A single colony of E.coli BL21(DE3) cells containing the expression 
vector was inoculated overnight in a 10 ml LB medium with 100 µg/ml of ampicillin. 
2 ml of overnight culture was transferred into a 1L LB medium containing 100 µg/ml 
of ampicillin. The culture was grown at 37
o
C until OD600 reached 0.6. The 
recombinant protein expression was induced with 0.35 mM of IPTG. The culture was 
further grown for 16 hours at at 20
o
C. The cells were harvested by using a 
centrifugation process at 8000 rpm for 40 minutes.  Then, they were resuspended in a 
25 ml of Nickel binding buffer containing 20 mM of Tris-Cl at a pH of 8.0, 0.5 M of 





C labeled protein samples, the expression was carried out 
using a M9 minimal media with the similar expression conditions as mentioned 
above. In the M9 media, a 1g/L of 
15
N ammonium chloride was used as the sole 
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nitrogen source to express 
15
N of labeled protein. 1g/L of 
13
C glucose was used as a 
sole carbon source to label the 
13
C protein. 
2.3.2       His-tagged protein purification using Nickel-affinity chromatography 
The His-tagged protein was purified using Nickel-affinity chromatography. 
The cells from the 2L culture were harvested and resuspended in 50 ml of Nickel 
binding buffer containing 20 mM Tris-Cl with a pH of 8.0, 0.5 M of NaCl, and 5 mM 
of immidazole. The cell suspension was lysed by sonication in a cold room and 
subsequently centrifuged at 18000x g for 30 minutes. The supernatant was loaded 
onto the Nickel column.  Then, the column was washed 10 times with a total volume 
of 500 ml Nickel washing buffer containing 20 mM of Tris-Cl with a pH of 8.0, 0.5 M 
of NaCl, and 30 mM of immidazole to remove the unbound proteins. The 
recombinant protein with His-tag was eluted with 30 ml of elution buffer containing 
20 mM Tris-Cl pH 8.0, 0.5 M NaCl, and 500 mM immidazole. The eluted protein was 
dialyzed against 20 mM Tris-HCl pH 8.0 and 200 mM NaCl to remove the imidazole. 
The His-tag could be removed by using thrombin digestion or factor Xa digestion. 
The digested mixture could be further purified using gel filtration chromatography. 
2.3.3       GST-tagged protein purification using glutathione-sepharose affinity 
chromatography 
The GST-tagged protein was purified using glutathione-sepharose affinity 
chromatography. The cells from the 2L culture was harvested and resuspended in 50 
ml of PBS (140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4 and 1.8 mM KH2PO4, pH 
7.4). The cell suspension was lysed by sonication in a cold room and subsequently 
centrifuged at 18000x g for 30 minutes. The supernatant was carefully collected and 
loaded onto the glutathione-sepharose beads (Amersham Biosciences).  The column 
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was washed 20 times with a total volume of 700 ml of 1x PBS buffer to remove 
unbound proteins. The recombinant protein with a GST tag was eluted with 25 ml of 
glutathione elution buffer (50 mM Tris-Cl, pH 8.0 and 10 mM reduced gluthathione). 
The GST-tag could be separated by the process of thrombin digestion and the digested 
mixture could be further purified using gel filtration chromatography. 
2.3.4       Thrombin digestion 
After being purified by Nickel-column or GST column, the recombinant 
protein still contained unwanted His-tag or GST tag. These tags could be removed 
from the recombinant proteins by thrombin digestion. To cleave His-tag or GST tag 
from 1 mg of recombinant protein, 2 U of Thrombin was used. The digestion was 
carried out in a buffer containing 50 mM Tris-Cl (pH 8). The digestion time ranged 
from 1 hour to overnight depending on the protein. The digestion was analyzed by 
using SDS-PAGE. The cleaved tag and thrombin was then removed by gel filtration. 
2.3.5       Factor Xa digestion 
After removing the fusion tags (His-tag and GST-tag) by using thrombin 
digestion, the recombinant protein still contains 2 unwanted amino acid residues 
(glycine and serine) at the N terminal. These two extra amino acid residues at the N-
terminal may interfere with the function of the recombinant protein, especially small 
protein and peptides like dermcidin. To solve this problem, we have inserted the 
factor Xa digestion site at the beginning of the genes encoding for the DCD peptides. 
To cleave fusion tags from 1 mg of recombinant protein, 0.5 U of Factor Xa was used. 
The removal of the fusion tags by Factor Xa was carried out in 1x PBS. The digestion 
was carried out at room temperature for 4 hours. The digestion was analyzed by using 
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SDS-PAGE. The cleaved tag and Factor Xa were then separated by using gel 
filtration.  
 2.3.6       Protein purification using gel-filtration chromatography 
Gel-filtration chromatography was performed using suitable gel-filtration 
columns. For small protein (<60 kDa), a HiLoad 16/60 Superdex 75 pg column 
(Amersham Biosciences) was used. For big protein (mw>60 kDa) or protein forming 
dimer or higher oligomeric states, a HiLoad 16/60 Superdex 200 pg column 
(Amersham Biosciences) was used. The protein samples were concentrated using 
Amicon® Ultra centrifugal filters. The precipitated proteins were removed by a 
centrifugation process for 15 minutes at 4
o
C. The samples were further filtered with a 
0.22 µm syringe filter before being loaded onto a pre-equilibrated gel-filtration 
column. Gel-filtration FPLC was carried out using a suitable gel-filtration column on 
the AKTA FPLC System (Amersham Biosciences) with a suitable running buffer. The 
flow rate was maintained at 1 ml/min.  
2.3.7       Sodium dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE was performed according to a standard protocol (Sambrook, 
Fritsch et al. 1989). Briefly, a 15% SDS-PAGE gel was prepared according to the 
table described in Appendix I using the Mini-PROTEAN 3 system (Bio-Rad). 20 µl of 
protein sample was mixed with 20 µl of 2 X SDS loading buffer (50 mM Tris-HCl, 
100 mM DTT, 2% (w/v) SDS, 0.1% (w/v) bromophenol brue, 10% glycerol) in a 1.5 
ml eppendorf tube. The sample was mixed and boiled for 5 minutes before the 
centrifugation process at 13000 rpm for 5 minutes. Twenty microliters of sample was 
loaded into each well, and a constant current of 35 mA was applied until the marker 
dye reached the end of the gel (~45 minutes). The gel was stained with Coomassie 
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blue staining solution for about 30 minutes and then destained using destaining 
solution (7% Acetic acid, 5% methanol) for 5 hours. 
2.4     Protein characterization 
2.4.1       Circular Dichroism (CD) spectroscopy 
CD experiments were conducted with 20 µM of protein in 50 mM phosphate 
buffer at room temperature. CD spectra were acquired using a Jasco J-810 
spectropolarimeter (Jasco, Japan) with a Hellma quartz cuvette of 1.0 mm path length. 
The spectra were recorded at a wavelength range of 190–260 nm with 0.1 nm 
resolution using a scan speed of 50 nm/min and averaged for ten scans.  
 2.4.2       Thermal denaturation experiments 
Thermal denaturation experiments for NF-κB proteins were carried out at a 
wavelength of 218 nm using 100 µM of protein. The spectra were recorded at a 
temperature slope of 1˚C/min with a resolution of 0.1˚C over the range of 25˚C – 
75˚C. 
2.4.3       Antimicrobial assay 
2.4.3.1        Colony count assay 
Colony count assay for the testing of the antimicrobial activities of the DCD 
peptides was adapted from an antimicrobial assay method described by Schittek and 
co workers (2001). Briefly, a single colony of each bacterial strain was inoculated into 
10 ml of LB and grown overnight at 37
o
C. 1 ml of the overnight culture was 
transferred to 50 ml of LB and cultured until O.D600 reached 0.4. The cells were then 
harvested and washed twice with 10 mM phosphate buffer (pH 7.4). For each washing 
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step, the cells were spinned down at 3500 rpm for 10 minutes at 4
o
C. The supernatant 
was discarded, and then the cells were pipetted up and down gently in the phosphate 
buffer (pH 7.4). 50 µl of the bacterial suspension (10^6 cells) was mixed with 50 µl of 
phosphate buffer at pH7.4 which contained various concentrations of DCD peptides in 
eppendorf tubes. The tubes were incubated at 37
o
C for 4 hours (without mixing or 
with mixing every 30 minutes by pipetting up and down). The bacterial suspension 
was diluted 100 times with a phosphate buffer (pH 7.4). 100 µl of diluted bacterial 
mixture was plated onto an LB agar plate and incubated overnight at 37
o
C. The 
numbers of the colony forming units (CFU) were determined by counting the number 
of colonies on each plate. A control with just bacteria in the phosphate buffer is used 
as a negative control and the CFU is set to 100% for this control. The experiments 
were triplicated to estimate the error. 
2.4.3.2        Radial diffusion assay  
The antimicrobial activity of the DCD peptides was also tested against 
Bacillus megaterium and other bacterial strains using Radial Diffusion Assay 
(Takemura, Kaku et al. 1996). Briefly, a single colony of each bacterial strain was 
inoculated into 10 ml tryptic soy broth (TSB) and grown overnight at 37
o
C. 1 ml of 
the overnight culture was transferred to a 50 ml TSB and cultured until O.D600 
reached 0.4. The cells were then harvested and washed twice with 10 mM phosphate 
buffer (pH 7.4). For each wash, the cells were spinned down at 3500 rpm for 10 
minutes at 4
o
C, the supernatant was discarded, and then the cells were pipetted up and 
down gently in the same buffer.  The re-suspended bacteria was adjusted to a cell 
density of 1 x 10
8
 cells using sterile phosphate buffer (pH 7.4). 100 µl of bacteria (~ 1 
x 10
8
 CFU) was transferred to 10 ml of sterile, warm (40C) sodium phosphate buffer 
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containing 3 mg of powdered TSB medium, 1% (w/v) of low endosmosis-type 
agarose (Sigma) and a final concentration of 0.02% (v/v) Tween-20 (Sigma). The 
mixture was mixed well and poured onto a petri dish to form a uniform layer of ~ 2 
mm thickness. Evenly spaced wells on an agar layer were made by using a 3 mm 
diameter biopsy punch. For each well, 5 µL of solution containing different 
concentrations of DCD peptides or positive and negative control peptides were added.  
The plate was incubated for 3 h at 37C before pouring a layer of 1% (w/v) agarose 
containing double strength (6 mg) TSB media on top of the agar layer. The plate was 
then incubated at 37C for 6 h. The diameter of the clear zone (surrounding each well) 
was measured. The experiments were triplicated to estimate the error. 
2.4.3.3        Broth microdilution assay 
Antimicrobial acitivity of DCD peptides was also determined using a modified 
microdilution method (Wiegand, Hilpert et al. 2008). Briefly, a single colony of each 
bacterial strain was inoculated into 10 ml of Mueller Hinton Broth (MHB) and grown 
overnight at 37
o
C. 1 ml of the overnight culture was transferred to 50 ml of MHB and 
cultured until O.D600 reached 0.6. The bacterial culture was diluted with pre-
autoclaved MHB to a concentration of 10
6
 CFU/ml. 100 µl of diluted bacterial 
suspension (10
6
 CFU/ml) was transferred to each well of a 96-well microtiter plate. 
Each well was then added with 100 µl of MHB media containing different 
concentrations of DCD peptides. The solution was mixed by pipetting up and down 
gently. The well containing only the MHB medium was used as a sterile control. The 
well containing bacterial suspension was used as a growth control. The plate was 
incubated overnight at 37°C without shaking. The growth of the bacteria in each well 
was measured at OD600. The minimum inhibitory concentration (MIC) was the lowest 
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concentration that inhibited the visible growth of the bacteria compared with the 
control sample. The experiments were triplicated to estimate the error. 
2.4.4       Sequence alignment 
Protein sequences of dermcidin isoform 1 and 2 were acquired from GenBank 
(http://www.ncbi.nlm.nih.gov/). Protein sequence alignment was carried out using the 
ClustalW software from EMBL-EBI (http://www.ebi.ac.uk/Tools/msa/clustalw2/).  
Aligned amino acid residues were compared based on their different properties 
(charged residues/hydrophilic residues versus hydrophobic residues).  
2.5    Nuclear magnetic resonance and structural study of DCD peptides 
2.5.1       NMR chemical shift assignments  
For the two short peptides, SSL25 and SSL29, 2D TOCSY and 2D NOESY 
were used to assign chemical shifts and calculate structure based on the NOE 









H correlation peaks. 3D heteronuclear 
NMR experiments including 3D HNCACB, 3D CACB(CO)NH, 3D CC(CO)NH-
TOCSY, HCC(CO)NH-TOCSY and 3D HCCH-TOCSY were used to assign the 
backbone and side-chain chemical shifts. All the NMR experiments were performed 
using a Bruker AVANCE 800 MHz spectrometer with a cryoprobe. The obtained 
NMR data were processed using NMRPipe and NMRDraw (Delaglio, Grzesiek et al. 













N HSQC spectrum was used as a general map to link all the 




N HSQC spectra of DCD1L and DCD2 
were acquired at 25
o
C on the 800MHz NMR spectrometer. For the amide proton 
dimension, a total of 1280 complex points were collected at a spectral width (SW) of 
11160.7 Hz with a carrier frequency of 4.735 ppm. For the 
15
N dimension, 128 points 
were collected at a SW of 1621 Hz with a carrier frequency of 116.031 ppm.  
2.5.1.2        3D HNCACB and CBCA(CO)NH 
The CBCA(CO)NH and HNCACB experiments were used to assign backbone 





resonances of each amide group were correlated with Cα and Cβ of the preceding 





resonances of each amide group were correlated with not only Cα and Cβ of the same 
residue, but also the Cα and Cβ chemical shifts from the preceding residue (Wittekind 
and Mueller 1993). By combining data obtained from CBCA(CO)NH and 3D 
HNCACB experiments, backbone assignments of DCD1L and DCD2 could be 
completed. 
 CBCA(CO)NH experiments for DCD1L and DCD2 were carried out in  a 
similar setting. In the 
1
H dimension, a total of 1280 complex points were collected at 




C dimensions, 80 and 172 complex points were 







C dimensions were at 4.735 ppm, 116.035 ppm and 43.7 




2.5.1.3         3D CC(CO)NH-TOCSY and HCC(CO)NH-TOCSY         
After completing the backbone assignments, the next step that needs to be 




C side-chain resonances. To obtain the 
1
H side-chain 
resonances of DCD peptides, 3D HCC(CO)NH-TOCSY was acquired  (Montelione, 
Wuthrich et al. 1992). In the direct 
1
H dimension, 1280 complex points were collected 
at a SW of 11160.7 Hz. In the 
15
N and indirect 
1
H dimensions, 80 and 160 complex 
points were collected at the spectra widths of 1621.7 Hz and 6402.5 Hz respectively. 




N dimensions were at 4.735 ppm and 116.03 
ppm respectively.  
To obtain the 
13
C side-chain resonances of DCD peptides, 3D CC(CO)NH-
TOCSY was acquired (Grzesiek, Dobeli et al. 1992). In the 
1
H dimension, 1280 





80 and 160 complex points were collected at the spectra widths of 1621.7 Hz and 







were at 4.735 ppm, 116.035 ppm and 43.7 ppm respectively. 
2.5.1.4        3D HCCH-TOCSY 
To correlate the side-chain aliphatic proton and 
13
C resonances, the 3D 
HCCH-TOCSY experiment was acquired (Wang and Zuiderweg 1995). The protein 
sample for the 3D HCCH-TOCSY experiments were lyophilized and dissolved in 
100% D2O. In the direct 
1
H dimension, 1280 complex points were collected at a SW 




C dimensions, 60 and 180 complex points 
were collected at the spectra widths of 11160.7 Hz and 4426.7 Hz respectively. The 






C dimensions were at 4.735 ppm, 116.035 ppm 
and 43.7 ppm respectively. 
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2.5.2 NOE distance restraints 





N-edited Nuclear Overhauser Effect spectroscopy (NOESY) data 
was acquired with a mixing time of 100 ms to identify amide proton distance 
constraints. Each cross peak in a 
15
N-NOESY amide strip results from the nuclear 
overhauser effect (NOE) between amide protons with a nearby proton within around 5 
Å distance. In the direct 
1
H dimension, 1280 complex points were collected at a SW 






H dimensions, 88 and 200 complex points 
were collected at the spectra widths of 1621.79 Hz and 6882.3 Hz respectively. The 




N and indirect 
1
H dimensions were at 4.735 
ppm, 116.035 ppm and 4.735 ppm respectively. 




C labeled DCD samples for 
13
C-edited NOESY were lyophilized and 
dissolved in 100% D2O. The 3D 
13
C-edited NOESY spectra were acquired using a 
mixing time of 100 ms. Each cross-peak results from the nuclear overhauser effect 
(NOE) between a nearby proton with the particular proton attached to the backbone 
and side-chain of 
13
C. In the direct 
1
H dimension, 1280 complex points were collected 






H dimensions, 80 and 128 complex 
points were collected at the spectra widths of 4426.7 Hz and 4000 Hz respectively. 




C and indirect 
1
H dimensions were at 4.735 
ppm, 41.69 ppm and 4.735 ppm respectively. 
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2.5.3 NOE assignments and structure calculation 
After assigning all the backbone and side chain chemical shifts, NOEs from 
the 
15
N-edited NOESY and 
13
C-edited NOESY were assigned. The 
15
N-edited 
NOESY was particularly useful for identifying the unambiguous NOEs between NH-
NH and between NH-Hα. These NOEs were used to confirm the obtained backbone 
assignment. The secondary structure information derived from the Chemical Shift 
Index (CSI) was used to support the pattern of NOEs.  For the α-helical regions, 
unique, strong NOEs between dαN (i+4), and dαN (i+3) were normally observed. For the 
β-sheet regions, unique, strong NOEs between dαN (i+1) were often observed. 
All the information including the amino acid sequence, the list of chemical shifts, the 
assigned NOEs and the dihedral angles were used to calculate the structures using 
CYANA 2.1. An ensemble of 100 structures was generated and the 20 lowest-energy 
conformers were selected. The quality of the final structure ensemble was validated 
with PROCHECK (Laskowski, Rullmannn et al. 1996).  
2.6    The interaction of NF-κB p50 and p65 with their small inhibitors 
androgapholide and parthenlonide 
2.6.1       Computer docking 
The crystal structure of NF-κB p50 (PDB ID: 1NFK) was used for docking 
with andro and parthenolide using the program Autodock 4.0 (Morris, Goodsell et al. 
1998).  The initial 3D structure of andro and parthenolide were generated using the 
PRODRG server (Schüttelkopf and van Aalten 2004).  Coordinate files of the 
macromolecule as well as the ligand used for the autogrid and autodock calculations 
were prepared using the program AutoDockTools (Morris, Goodsell et al. 1998). A 
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grid with a spacing of 0.375 Å and 66x68x62 points or a spacing of 0.375 Å and 
82x82x82 points were used for andro and parthenolide, respectively.  The location of 
the grid center was selected to be at the residue Cys62 of p50.  The GA-LS algorithm 
was adopted using default settings except that the maximum number of generation 
was changed to 500,000 and the maximum number of energy evaluations was 
increased to 25,000,000.  For each of the docking jobs, a total of 100 hybrid GA-LS 
runs were carried out.  A total of 100 possible binding conformations were generated 
and grouped into clusters based on a 2.0 Å cluster tolerance. 
2.6.2       Determination of NF-κB/inhibitor complex formation by ESI-Qtof  
For each reaction, 1 ml of NF-κB protein (20 µM) in PBS (pH7.4) containing 
1 mM EDTA, 10 µM 2-ME, and 5% glycerol (v/v) was incubated with an inhibitor 
(andro/andro’s derivatives or parthenolide) at 37oC for 2 hours. The final 
concentration of inhibitor tested are 0, 40 µM, 80 µM , 160 µM, 200 µM and 1000 
µM. All of the inhibitors used in this study (andro, parthenolide, helenali etc.) were 
dissolved in 100% DMSO. The final DMSO concentration in each reaction was 
mantained at 1% (v/v)..After 2 hours of incubation at 37
o
C, the samples were added 
with 100 µl of glacial acetic acid and then filtered and injected into a reverse-phase 
column (Atlantis, dC18, 4.6x250 mm, 5 μm, Waters). The column was pre-
equilibrated with H2O containing 0.1% trifluoroacetic acid (TFA) and then washed 
with a gradient of 0-100% absolute acetonitrile containing 0.1% TFA. The NF-κB 
protein was collected and analyzed by using ESI-QTOF-MS (Synapt HDMS mass 
spectrometer, Waters, Manchester, UK). The samples were directly injected into the 
ESI source. The ESI-QTOF-MS instrument was operated in a positive ion mode. The 
optimal conditions of analysis were as follows. The flow rate, cone gas flow and the 
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desolvation gas flow were at 40 μl/min,50 L/h and 100 L/h respectively. The source 
temperature and desolvation gas temperature were at 80°C and 150°C respectively.  
The source spray voltage, capillary voltage, sampling cone voltage and the extraction 
cone voltage were at 3.5 kV,  3.5 kV,  35 V and 6.0 V respectively. The data acquired 
was between m/z 500 and 3000 Da. It was processed by using the MassLynx 4.1 
software (Waters).  
2.6.3       Electrophoretic mobility shift assay (EMSA)  
The p50 (20 µM) in PBS buffer (pH7.4) containing 1 mM EDTA, 10 µM 2-
Mercaptoethanol, and 5% glycerol (v/v) was incubated  with andro or parthenolide at 
37
o
C for 2 hours. The consensus oligonucleotide probes for NF-κB and the control 
(Table 2.3) were labeled with 6-fluorescein amidite (6-FAM). The oligonucleotides 
were purchased from 1
st
 Base (Singapore). The p50/drug complex was then 
exchanged to EMSA buffer containing 10 mM Tris-HCl (pH 7.4), 50 mM NaCl, 4% 
glycerol, 1 mM MgCl2, 0.5 mM EDTA, and 0.5 mM DTT. 30 µl reaction mixture 
containing 2 µM of p50 was incubated for 20 minutes in the presence of 250 µg/ml 
poly(dI-dC). The oligonucleotide probes were added to each of the reaction mixtures 
and incubated at 25°C for 20 minutes. For the negative binding control, p50 in the 
EMSA buffer with 250 µg/ml poly(dI-dC) was incubated with cold probe control (NF-
κB DNA without label) for 20 minutes before adding the oligonucleotide probes. The 
p50-DNA complexes were separated from the free DNA probes through 6% non-
denaturing polyacrylamide gels in 0.5x Tris-boric acid-EDTA buffer. Electrophoresis 
was performed at 10 mA. The gels were visualized using a Biorad gel documentation 










Table 2.3 List of primers used for EMSA of p50/ NF-κB site 
NF-κB site_forward: 5’ TCTGAGGGACTTTCCTGATCCGAACAGCCGAAACAACGTG 3’ 
NF-κB site_Reverse: 5’ CACGTTGTTTCGGCTGTTCGGATCAGGAAAGTCCCTCAGA 3’ 
Negative control of NF-κB 
site_forward: 
5’ TCTGAGGGACATTCCTGATCCGAACAGCCGAAACAACGTG 3’  
Negative control of NF-κB 
site_Reverse: 




CHAPTER 3.    STRUCTRURAL STUDIES OF THE HUMAN 
ANTIMICROBIAL PEPTIDE DERMCIDIN  
3.1    SUMMARY 
The worldwide problem of growing antibiotic resistance has drawn much 
research attention to naturally occurring antimicrobial peptides (AMPs) as potential 
alternative antimicrobials. Dermcidin (DCD) is a human antimicrobial peptide.  It 
shows a broad spectrum of antimicrobial activities against a variety of pathogenic 
microorganisms. These microorganisms include Gram-positive, Gram-negative 
bacteria, fungus and even drug-resistant S. aureus, rifampin- and isoniazid-resistant 
Mycobacterium tuberculosis (Schittek, Hipfel et al. 2001). Although DCD shares 
similar antimicrobial activities with other antimicrobial peptides, it has no sequence 
homology to other known antimicrobial peptides, and seems to be unique. Its specific 
method of killing microbes is still unknown to date. In this study, four different 
fragments of DCD peptides, DCD1L, SSL29, SSL25 and DCD2 carrying distinctly 
different charges and isoelectric points (pI) are chosen for the structural studies to 
deduce their antimicrobial mechanisms. Detailed information on the structure and the 
lipid binding affinities of different DCD peptides will help to design better peptides 
with optimal functional residues. 
3.2    INTRODUCTION 
3.2.1 Antimicrobial peptides (AMPs) 
AMPs are peptides that are involved in the elimination of pathogenic 
microorganisms from their host. AMPs are produced by almost all the species of 
living organisms ranging from bacteria through insects to humans (Lapis 2010; Meng, 
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Xu et al. 2010). Most AMPs can kill a broad-spectrum of microorganisms including 
Gram-positive and Gram-negative bacteria, viruses, fungi, and parasites. Some AMPs 
can even kill cancer cells (Lehmann, Retz et al. 2006; Hoskin and Ramamoorthy 
2008; Lapis 2010). AMPs have evolved in living organisms over a period of 2.6 
billion years to combat continuously evolving pathogenic microorganisms (Gordon, 
Romanowski et al. 2005). They are often effective against multidrug-resistant cells. 
Many AMPs even have the ability to enhance immunity by acting as 
immunomodulators (Holzl, Hofer et al. 2008; Ramos, Silva et al. 2011). Hence, 
understanding the mechanism and structure-activity relationship of these peptides is 
very important to design a highly specific and potent antimicrobial peptide. 
3.2.2 Classifications of AMPs 
AMPs are a diverse group of molecules, which are classified based on source, 
length, sequence, amino acid composition, and structures (Yeaman and Yount 2003; 
Yount and Yeaman 2005). Most AMPs are small peptides ranging from 12 to 50 
amino acids. Their amino acid composition typically consists of positively charged 
residues (arginine, lysine) and hydrophobic residues (Sitaram and Nagaraj 2002; 
Papagianni 2003). Many AMPs are unstructured in an aqueous solution and adopt a 
final structural configuration upon interaction with the amphipathic phospholipid 
membrane (Yeaman and Yount 2003). Based on the final secondary structures, AMPs 
are categorized into 4 groups including (1) α-helical, (2) β-stranded, (3) loop, and (4) 
extended structures. Despite the structural differences, AMPs peptides usually share 
amphipathic features with the hydrophilic amino acid residues aligned along one side 
and the hydrophobic amino acid residues aligned along the opposite side of the 
molecules (Yeaman and Yount 2003; Yount and Yeaman 2005). This feature is 
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crucial for AMPs as it allows AMPs to associate with the biological membrane 
(Hancock and Rozek 2002).  
AMPs are also categorized based on length, net charge, amino acid 
composition and special characters described below. 
a. Anionic peptides   
Anionic peptides are short peptides (5-70 aa) and have negative net charges 
ranging from -1 to -7 (Harris, Dennison et al. 2009). They are usually rich in glutamic 
and aspartic amino acids and require zinc as a cofactor for exhibiting their 
antimicrobial activity. They are active against both Gram-positive and Gram-negative 
bacteria, fungi, viruses and even insects (Brogden, Ackermann et al. 1998; Harris, 
Dennison et al. 2009). Anionic AMPs are found in many organisms across the 
eukaryotic kingdom such as plants, e.g. hevein (Marcus, Green et al. 1999); 
amphibians, e.g. maximin H5; insects, e.g. MDpep5 (Tang, Shi et al. 2008) and 
humans, e.g.  dermcidin (Schittek, Hipfel et al. 2001; Rieg, Garbe et al. 2004).  
b. Linear cationic α-helical peptides 
These are short and linear peptides with positive net charges. They lack 
cysteine residues that may form disulfide bonds. They are generally unstructured in 
aqueous solution but upon interaction with biological membranes, they adopt a α-
helical structure. The increase in the helical content is proven directly proportional to 
their activity (Gennaro et al., 2000; Tossi et al., 2000). Linear cationic α-helical 
peptides are found in many organisms such as plants, e.g. palicourein, amphibians, 
e.g.  magainin, insects,  e.g. cecropins and humans, e.g. LL37 (Hancock and Lehrer 
1998; Brown and Hancock 2006; Lai, Adhikarakunnathu et al. 2011). 
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c. Cationic peptides rich in specific amino acid groups 
These are also short cationic peptides ranging from 12 to 50 amino acids. They 
also lack cysteine residues, but they are distinct from the normal cationic peptides  as  
they  are  rich  in particular  residues  such as  proline,  arginine,  phenylalanine, 
glycine or tryptophan. They are found in many organisms such as honeybees, e.g. 
apidaecins, rich in proline and arginine (Casteels, Ampe et al. 1989); pigs, e.g. PR-39, 
rich in proline and arginine (Cabiaux, Agerberth et al. 1994); cattle, e.g. indolicidin, 
rich in tryptophan (Selsted, Novotny et al. 1992). 
d. Disulfide bonded anionic and cationic peptides 
This group of AMPs is distinct from the normal anionic or cationic peptides as 
they contain cysteine residues, which can form a stable disulfide bond. This group of 
peptides can be further divided into different subgroups based on the number of 
cysteine residues and other conservatory residues they have. These peptides are found 
in many organisms such as horseshoe crabs, e.g. tachyplesins with two disulphide 
bonds (Iwanaga, Muta et al. 1994); fruit flies, e.g. drosomycin with three disulphide 
bonds (Zhang and Zhu 2009); and humans, e.g. defensin with three disulfide bonds 
(Schroder and Harder 1999). 
3.2.3 Antimicrobial activity 
AMPs have evolved in living organisms over a period of 2.6 billion years and 
they have developed sophisticated mechanism of action to combat continuously 
evolving pathogenic microorganisms (Gordon, Romanowski et al. 2005). Different 
AMPs have different mechanisms of action including disrupting membranes, 
interfering with bacterial metabolism, and targeting bacterial cytoplasmic 
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components. For membrane disrupting AMPs, three common modes of action have 
been proposed including the toroidal model, the carpet model, and the barrel-stave 
model. These models are shown in Figure 3.1 and briefly described below. 
1) Toroidal model 
In the toroidal model (Figure 3.1A), AMPs in the extracellular environment 
adopt a α-helical conformation as they interact with the bacterial membrane. Initially, 
the α-helical AMPs are arranged parallel to the membrane surface. The hydrophobic 
part of the attached peptides inserts into the hydrophobic core of the membrane, 
creating a gap in the hydrophobic core of the membrane. When the ratio of AMP-to-
lipid reaches a threshold, the AMPs will aggregate and orient perpendicular to the 
membrane, forming a transmembrane channel. The transmembrane channel is made 
of both the inserted peptides and the lipid’s hydrophilic head groups. 
2) Carpet model 
In the carpet model (Figure 3.1 B), AMPs arranged parallel to the surface of 
target membrane. The accumulation of AMPs on the membrane surface affects the 
membrane fluidity and/or reductions in membrane barrier properties. When the 
accumulation of AMPs reaches a threshold, the membrane integrity is lost and the 
membrane will be disrupted (Sitaram and Nagaraj 1999). In this model, AMPs do not 
need to insert into the hydrophobic core of the membrane or form transmembrane 
channels.  
3) Barrel-Stave model 
In this model (Figure 3.1 C), AMPs bind to the membrane surface and adopt 
an amphipathic structure. The hydrophobic portion of AMPs insert into the 
hydrophobic region of a membrane. The positively charged portions of AMPs interact 
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with the negatively charged headgroups of the membrane phospholipid. When the 
concentration of AMPs reaches a threshold, the AMPs self-aggregate and insert into 
the membrane, forming a transmembrane channel.  
Although these three models are significantly different from each other, they 
all agree that the initial phase of antimicrobial action should start with the electrostatic 
interactions. This electrostatic attraction is considered a crucial property of AMPs that 
decide the selectivity of these peptides. Cationic portions of  AMPs  become  attracted  
to  the  anionic  phospholipids  bilayer membrane of the bacteria and not to the 
zwitterionic  membrane in the case of human cells.  
 
Figure 3.1 Proposed models for the membrane disruption of antimicrobial peptides 
(A)  Torroidal model (B) carpet model and (C) Barrel-Stave  model. For all the models, 




3.2.4 Selectivity of AMPs towards bacterial and mammalian membranes  
Bacterial and mammalian membranes are significantly different. Bacterial 
membrane predominantly contains phosphatidylglycerol (PG), and cardiolipin (CL) 
(Table 3.1) (Yeaman and Yount 2003). As PG and CL are negative in their net 
charges, bacterial membranes tend to be highly electronegative. In contrast, 
mammalian membranes predominantly contain phospholipids 
phosphatidylethanolamine (PE), phosphatidylcholine (PC), sphingomyelin (SM), and 
phosphatidylserine (PS). As PC, SM and PE normally have no net charges, the net 
charges of mammalian membranes tend to be neutral. 
The differences between the bacterial and mammalian membrance can be 
potentially exploited by antimicrobial peptides. Bacterial membranes are usually rich 
in negatively charged phospholipids PG and CL (Chou, Kuo et al. 2008; Matsuzaki 
2009). Therefore, bacterial membranes are usually more attractive to the attack of 
positively charged AMPs. Many studies have shown that most AMPs selectively 
interact with bacterial membranes, but not mammalian membranes (Taheri-Araghi 
and Ha 2007; Lee, Park et al. 2009; Schmidtchen, Ringstad et al. 2011). This selective 
property of AMP enables them to kill microorganisms without being significantly 
toxic to mammalian cells (Matsuzaki 2009). Some AMPs have low membrane 
selectivity, which are toxic to both the host cells and the pathogen cells (Chen, 
Niyonsaba et al. 2006). To attenuate the toxicity of these AMPs, the expression and 
the localization of these AMPs are tightly regulated by the host cells (Yount and 
Yeaman 2005). The selective property of AMPs is a very important feature of AMPs. 
Hence, understanding the selectivity mechanism in AMPs is very important in order 
to design better therapeutic AMPs.  
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Among lipids unique for the mammalian cell, PCs are generally the most 
dominant (Table 3.1). Therefore, the membrane model containing PCs are usually 
used as the mammalian membrane mimicking model. Meanwhile, among lipids 
unique for bacterial cells, PGs are generally the most dominant (Table 3.1). Hence the 
membrane model containing PGs are usually used as a bacterial membrane mimicking 
model. 
Table 3.1 Lipid composition of eukaryotic and bacterial membranes by average 
weight % of total lipids 
Cell/Organelle PC PE PS PG PI SM CL Ste 
Erythrocyte (human) 20 16 5 0 0 20 0 23 
Erythrocyte (rat) 34 11 1 0 0 16 0 28 
Myelin (rat brain) 11 14 7 0 0 6 0 22 
Nuclear membranes (rat liver) 55 20 4 0 9 3 0 9 
E. coli (inner membrane)  0 60 0 33 0 0 7 0 
E. coli (outer membrane)  0 61 0 13 0 0 1 0 
Bacillus subtilis  0 13 0 77 0 0 4 0 
Adapted from Warschawski and coworkers (2012) 
3.2.5 Dermcidin - the human antimicrobial peptide 
Dermcidin (DCD) is a human antimicrobial peptide, which is constitutively 
and specifically expressed in the eccrine sweat glands within the dermis of human 
skin (Schittek, Hipfel et al. 2001). It is secreted into sweat and transported to the skin 
surface (Schittek, Hipfel et al. 2001). DCD plays an important role in the innate host's 
defense by building a constant barrier that overlies the epithelial skin. DCD shows a 
broad spectrum of antimicrobial activities against a variety of pathogenic 
microorganisms, including Gram-positive bacteria (Staphylococcus aureus), Gram-
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negative bacteria (Escherichia coli and Enterococcus faecalis), and fungus (Candida 
albican) (Schittek, Hipfel et al. 2001). More interestingly, DCD is even effective 
against drug-resistant S. aureus, rifampin-resistant and isoniazid-resistant 
Mycobacterium tuberculosis (Schittek, Hipfel et al. 2001).  The reduction of 
dermcidin in the sweat weakens the skin barrier and may lead to chronic skin diseases 
such as atopic dermatitis (Zhang and Falla 2010).  
Although DCD shares similar antimicrobial activities with other antimicrobial 
peptides, it has no sequence homology compared to other known antimicrobial 
peptides, and seems to be unique. Its specific method of killing microbes is still 
unknown to date. Furthermore, unlike most antimicrobial peptides that are cationic 
peptides, full-length antimicrobial DCD is anionic, with a net charge of −2. This 
suggests that the mechanism of action of DCD may be different from those of most 
cationic antimicrobial peptides. Anionic antimicrobial peptide DCD is thus a very 
interesting antimicrobial peptide to study.  
 
Figure 3.2 Dermcidin precursor 
 
DCD precursor (Figure 3.2) consists of 110 amino acids (aa) with a N-
terminal 19 aa signal peptide, a 30 aa survival promoting peptide in between and a 48 
aa antimicrobial peptide at the C-terminus. The active antimicrobial DCDs are derived 
from 48 aa residues at the C-terminal region named DCD1L. DCD1L is further 
cleaved by aspartate protease cathepsin D to generate shorter DCD fragments 
(Baechle, Flad et al. 2006; Rieg, Seeber et al. 2006). A total of 14 proteolytically 
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processed DCD peptides were identified in sweat using the SELDI-TOF mass 
spectrometry (Rieg, Seeber et al. 2006). In sweat, 1-10 μg/ml of DCD1 (derived from 
DCD1L with the last leucine residues removed) is toxic to most microorganisms 
(Schittek, Hipfel et al. 2001; Flad, Bogumil et al. 2002).  
DCD1L is very flexible and its secondary structure is highly dependent on the 
surrounding solutions. Previous studies indicated that DCD1L exists as a random coil 
conformation in an aqueous buffer but adopts a α-helical conformation when 
associated with SDS (Senyurek, Paulmann et al. 2009; Paulmann, Arnold et al. 2012). 
Immunoelectron microscopy studies indicated that DCD1L is able to bind to the 
bacterial surface, which suggests that DCD1L may interact with the lipid membrane 
or the membrane components and change its conformation. 
The structural study of DCD peptide in bacterial membrane mimicking 
environments is essential for an in-depth understanding of their activity, mechanisms 
of actions, and in guiding peptide design. The structure of DCD1L induced by 50% 
TFE (trifluoroethanol) solution has been solved recently (Jung, Yang et al. 2010). 
However, a 50% TFE solution may not be a good simulation of the bacterial 
membrane environment. Thus, the 3D structure of DCD1L in 50% TFE may not the 
same as the 3D structure of the bacterial membrane bound DCD1L. Our preliminary 
far-UV CD results indicated that the DCD1L structure induced by 50% TFE is 
significantly different from the DCD1L structures induced by SDS (Sodium dodecyl 
sulfate) and POPG (palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol). We propose 
to study the structures of DCD peptides in SDS, POPG and other membrane 
phospholipids to investigate the relationship between the structure and function of 
DCD peptides. Detailed information on structure and the membrane binding 
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properties of the different DCD peptides will allow us to design shorter peptides with 
optimal functional residues. In addition, the DCD peptide has no hemolytic activity 
against human red blood cells even at up to 100 μM (Li, Rigby et al. 2009). Thus, this 
property allows it to be developed as an effective therapy to replace chemical 
antibiotics that usually lead to the appearance of multi-resistant bacterial strains.  
Among the 14 DCD peptides, DCD1L, SSL29 and SSL25 are chosen for their 
structural studies as they carry distinctly different charges, and isoelectric points (pI). 
DCD1L is anionic (charge of -2, pI of 5.07 and M.W. of 4.82 kDa), SSL29 is neutral 
(charge of 0, pI of 5.97 and M.W. of 2.87 kDa) and SSL25 is cationic (charge of +2, 
pI of 9.4 and M.W. of 2.33 kDa). Despite their different charges and pI, all these DCD 
peptides have overlapping killing spectra (22). In addition, an isoform of DCD, 
termed DCD2 (pI of 6.1 and M.W. of 5.95 kDa), which has recently been identified in 
gestational tissue (Lee Motoyama, Kim-Motoyama et al. 2007) is also selected for the 
structural study. TFE, bacterial membrane mimicking agents (SDS, D8PG, POPG and 
lipid A) and eukaryotic membrane mimicking agents (DPC and POPC) were used to 
induce structures in these peptides. 
DCD1L SSLLEKGLDGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSVL  
SSL29 SSLLEKGLDGAKKAVGGLGKLGKDAVEDL  
SSL25 SSLLEKGLDGAKKAVGGLGKLGKDA  
DCD2  SSLLEKGLDGAKKAVGGLGKLGKDAVEDLESVGKGGEERLVFGAPVNLTSIPLTSVSRP  
 
3.3    RESULTS AND DISCUSSION 
3.3.1 Design, expression and purification of DCD peptides 
DNA fragments of the DCD1L, DCD2 were sub-cloned into the expression 
vector pET-M containing an 6xHis-tag at N-terminal for purification. The resulting 
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pET-M-DCD1L, and pET-M-DCD2 constructs were then transformed into BL-
21(DE3) competent cells for expression. Recombinant DCD1L, and DCD2 peptides 
were purified by Nickel-affinity column.  
From Figure 3.3, it can be seen that soluble DCD1L was expressed in E.coli 
BL-21(DE3).  Highly pure DCD1L peptide was obtained after being purified using 
Nickel-affinity column. Typically, one liter of LB media yielded 5 mg of soluble 
DCD1L peptide. His-tag was removed from the peptide by using Factor Xa digestion. 
The digested mixture was loaded onto a Superdex 75-PG gel filtration column 
(Pharmacia). The DCD1L peptide was eluted out at 75 ml (Figure 3.4). The SDS-
PAGE analysis of gel filtration fraction confirms that DCD1L was eluted at 
approximately 75 ml, which suggests that DCD1L exists as a monomer.  
DCD2 was also expressed in a soluble form in E.coli BL21(DE3) cells (Figure 
3.5 A).  Highly pure DCD2 peptide could be purified by using Nickel-affinity column. 
Each liter of LB media yielded approximately 4-6 mg of soluble DCD2 peptide. After 
the removal of the His-tag from the peptide by using Factor Xa digestion, the digested 
mixture was then loaded onto a Superdex 75-PG gel filtration column (Pharmacia). 
The Gel filtration profile (Figure 3.5 B) showed that the DCD2 peptide was eluted out 
at 75 ml. The SDS-PAGE analysis of gel filtration fraction confirms that DCD2 was 
eluted at approximately 75 ml, which suggests that DCD2 exists as a monomer. 
SSL25 and SSL29 peptides are chemically systhesized by 1
st




Figure 3.3 Expression and purification of DCD1L. 
DCD1L was expressed as a soluble peptide in E. coli BL21(DE3). Lane 1, protein marker; 
lane 2, Pellet obtained from sonication and centrifigation; lane 3, supernatant, lane 4, flow-





Figure 3.4 Gel filtration profile and SDS-PAGE analysis of DCD1L 
  (A) Gel filtration profile of DCD1L on a Superdex 75-PG gel filtration column 
(Pharmacia). The peak corresponding to DCD1L is indicated by an arrow. (B) SDS-
PAGE analysis of gel filtration fraction confirms that DCD1L was eluted at 






Figure 3.5 Gel filtration profile and SDS-PAGE analysis of DCD2 
 (A) Gel filtration profile of DCD2 on Superdex 75 PG column. The peak corresponding 
to DCD2 is indicated by an arrow. (B) SDS-PAGE analysis of gel filtration fraction 




3.3.2 Conformational changes of DCD peptides upon binding to membrane 
models 
We investigated the changes of the secondary structure of DCD peptides 
(SSL25, SSL29, DCD1L and DCD2 in buffers containing TFE, bacterial membrane 
mimicking agents (SDS, D8PG, POPG and lipid A) and eukaryotic membrane 
mimicking agents (DPC and POPC) (Figure 3.6). DPC, SDS, D8PG can form 
micelles which are good for CD and NMR experiments. POPG and POPC can form 
vesicles, which can mimick the membrane bilayer better than micelles. Vesicles are 
good for CD experiments but too big for solution NMR studies. The structural 
changes of DCD peptides upon binding to membrane mimicking models are 
summarized in Table 3.2. 
From Figure 3.7, it can be seen that all the four DCD peptides adopt random 
coil structures in the sodium phosphate buffer. However, in the presence of TFE, SDS 
or bacterial membrane mimicking agents (POPG), they all adopt an α-helix structure. 
This result suggests that DCD peptides bind to lipid micelles or vesicles and change 
its structural conformation from a random coil to an α-helix structure. This indicates 
that DCD peptides share a common property with many antimicrobial peptides as they 
also exist as random coils in unbound form and adopt an α-helix structure in lipid 
bound form. 
 Despite the fact that DCD peptides adopt α-helix structures in the presence of 
TFE, SDS, or bacterial membrane mimicking environments, POPG, the α-helical 
content of DCD peptides induced by these agents is significantly different. From 
Figure 3.7, it is obvious that the α-helical content of the DCD peptide induced by 50% 
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TFE is significantly lesser than that induced by 30 mM SDS and 4 mM POPG. This 
result agrees with previous studies reported by Jung et al. 2010 (Jung, Yang et al. 
2010) that found that the α-helical content of DCD1L induced by 50% TFE is 
significantly lesser than that induced by SDS. This result suggests that the structure of 
DCD1L induced by 50% TFE should be significantly different from that induced by 
SDS and POPG. Interestingly, the α-helical structures of DCD peptides induced by 
SDS are quite similar to those induced by POPG. This result also agrees with previous 
studies conducted by Paulmann and coworkers (2012) that DCD1L adopts an α-helix 
structure in the presence of POPG vesicles (Paulmann, Arnold et al. 2012). As POPG 
is the best bacterial membrane-mimicking environment, this result indicates that SDS 
is a better bacterial membrane-mimicking model for solving 3D DCD peptides’ 
structures compared to 50% TFE. Therefore, it is worth studying the 3D structure of 
DCD1L in SDS, which can help us to understand the mechanisms of actions and 
membrane-binding properties of the DCD peptides. 
It is important to note that the POPC vesicles did not induce any helical structures for 
any DCD peptides (Figure 3.7). This result suggests that the DCD peptides 
specifically interact with bacterial membrane-mimicking model (SDS, D8PG and 
POPG) but not with eukaryotic membrane-mimicking model (POPC). This result also 
indicates that DCD peptides share specificity with other types of antimicrobial 









Figure 3.6 Detergent and lipids used to mimick bacterial and mammalian membrane  
Structure of TFE, bacterial membrane-mimicking agents (SDS, D8PG, POPG, lipid A) 
and eukaryotic membrane-mimicking agents (DPC, POPC). DPC: 
Dodecylphosphocholine; POPC:1-palmitoyl 2-oleoyl sn-glycerol-3 phosphatidyl-rac-
glycerol; POPG: 1-palmitoyl 2-oleoyl sn-glycerol-3 phosphatidyl-rac-glycerol; D8PG: 
1,2-dioctanoyl-sn-glycero-3-phospho-(1'-rac-glycerol) SDS: Sodium Dodecyl Sulphate. 
DPC, SDS, D8PG can form micelles which are good for CD and NMR experiments. 
POPG and POPG can form vesicles, which can mimick membrane bilayer better than 









Table 3.2 Secondary structures of SSL25, SSL29, DCD1L and DCD2  
induced by detergent and lipids 
Bacterial membrane-mimicking agents (SDS, D8PG, POPG, lipid A) and eukaryotic 



















Figure 3.7 Circular Dichroism spectra of DCD peptides under different conditions 
Far UV CD spectra of SSL25 (A), SSL29 (B), DCD1L (C) and DCD2 (D) in 50% TFE 










3.3.3 Solving the structure of DCD1L using NMR 








N labeled DCD1L was obtained by growing the bacteria in M9 minimal 
media with 
15
N ammonium chloride as the sole nitrogen source. The DCD1L/SDS 
samples containing 1 mM peptide and 60-fold of deuterated SDS (Cambridge Isotope 
Laboratories) were prepared for the NMR studies. Samples of DCD1L in DPC or 
POPG were also prepared using 1 mM 
15
N DCD1L peptides with 60-fold deuterated 
DPC or 30-fold POPG (Avanti lipids, AL).  
 









N HSQC spectra of DCD1L was acquired using a Bruker 800 MHz NMR 
machine at 25
o
C in 20 mM phosphate buffer, pH8, 100 mM NaCl with the absence of 









N HSQC spectrum of DCD1L was acquired 
using a Bruker 800 MHz NMR machine at 25
o
C in 20 mM phosphate buffer, pH8, 
100 mM NaCl in the absence of SDS (Figure 3.8 A) or in the presence of 60 mM SDS 




N HSQC spectrum of 
DCD1L in the absence of SDS indicating that the structure of DCD1L in the absence 
of SDS is in intermediate conformational exchange on the NMR timescale and most 




N HSQC spectrum of DCD1L in the presence of 
60 mM SDS (Figure 3.8 B) showed a good dispersion of amide peaks with most of 
them having similar intensities. Forty five peaks out of the theoretical forty eight 
peaks were observed. It was later identified that Ser-1, Ser-2 and Val-14 were missing 




N HSQC spectrum. Amongst the 3 missing peaks, Ser-1 and Ser-2 are 
located at the end of the N-terminal of DCD1L which would not significantly affect 
structural calculation. By using the 3D spectrums (CC(CO)NH, HC(CO)NH and 
15
N-
edited NOESY),  information about the Ser-1, and Ser-2 side chain chemical shifts 
and NOEs could be obtained and included in the final structural calculation. Some 
unassigned, small peaks could result from the different conformation, which exist in a 




N HSQC spectrum were resolved and successfully assigned. 
3.3.3.2        Chemical shift assignment of DCD1L 
Backbone chemical shifts of DCD1L in SDS were assigned using two NMR triple 
resonance experiments, namely HNCACB and CBCA(CO)NH. The HNCACB 
experiment was used to connect all the amide peaks with the Cα and Cβ resonances of 
the same residue as well as the Cα and Cβ chemical shifts from the preceding residue 
(Figure 3.9 A). The CBCA(CO)NH experiment was used to connect the amide peaks 
with the Cα and Cβ resonances of the preceding residue (Figure 3.9 B). The amide 
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peaks were then linked together based on the connection of amide peaks with intra-
residue Cα and Cβ resonances (HNCACB) and inter-residue Cα and Cβ resonances 
(CBCA(CO)NH). The links between the amide peaks were then fitted into the 
sequence of DCD1L aided by the signature Cα and Cβ chemical shift values of certain 
amino acids. For example, Alanine has unique Cβ chemical shift values, which 
usually appear at ≤20 ppm, much lower than other residues. Serine and threonine 
residues also have distinctive Cβ chemical shifts values, which are higher than their 
Cα chemical shifts. In the HNCACB spectrum, Cβ of serine and threonine cross-
peaks are negative peaks. Thus, they can be easily identified in the amide strips. 
Another typical residue used for the initial fitting is Gly residues that only have a Cα 
cross-peak appearing in the HNCACB spectrum. 
By using 3D HNCACB and CBCA(CO)NH experiments, the backbone amide 
peaks of DCD1L were successfully assigned. The obtained assignment of amide 




N HSQC is shown in Figure 3.8 B. The sequential 
assignment of Cα and Cβ peaks from the residue K20 to E30 is shown in Figure 3.9.  
The remaining chemical shifts for the side-chain carbon was obtained from the 
CC(CO)NH experiment. The chemical shifts for the side-chain proton was obtained 
by using 3D 
15





Figure 3.9 Sequential assignment of backbone chemical shifts of DCD1L 
 A. Strip plots of HNCACB experiment, showing amide strips with Cα and Cβ resonances 
of the same residue from residues Lys-20 to Glu-30 as well as Cα and Cβ of the preceding 
residues. Negative peaks correlating to Cβ resonances are displayed in red. B. 
CBCA(CO)NH experiment showing amide strips correlating to Cα and Cβ resonances of 






3.3.3.3       Chemical shift index (CSI) 
After completing the backbone assignment of DCD1L, we utilized the 
experimental Cα and Cβ chemical shifts of all the residues to determine the chemical 
shift index of DCD1L. The calculated chemical shift index of DCD1L can be used to 
determine its secondary structure and boundaries (Wishart and Sykes, 1994). The 
chemical shift index was calculated based on following formula: 
                                           CSI = (Cα - CαRC) - (Cβ – CβRC) 
Cα and Cβ are chemical shifts of C-alpha and C-beta of the same residue 
obtained from experiments. CαRC and CβRC are standard random coil chemical shift 
values of the same type of amino acid. If the CSI value of a residue is positive, it 
suggests that the residue adopts an α-helix secondary structure. If the CSI value of a 
residue is negative, it suggests that the residue adopt a β-strand conformation 
(Wishart, Sykes et al. 1992),  
The CSI values obtained from all the amino acid residues of DCD1L were 
used to plot a chart (Figure 3.10). From the CSI plot, it can be seen that DCD1L 
comprises of three α-helices, which are probably connected by two turns or loops. 
This result suggested that DCD1L adopts a well-defined α-helix structure in bacterial 








Figure 3.10 Chemical Shift Index of DCD1L    
The CSI of SDS bound DCD1L was generated using the chemical shift values of all 
Cα and Cβ extracted from the triple resonance experiments. The secondary structure 
represented by the CSI plot is shown on top of the figure. The overall plot indicates 




3.3.3.4       Torsion angle restraints by TALOS 
 
The TALOS program was used to predict the angular restraints for the 
structural calculation of DCD1L. By employing the sensitivity of the backbone atom 
chemical shifts to local conformation, the TALOS program can predict the torsion 
angles phi (Φ angle) and psi (Ψ angle) of proteins (Cornilescu, Delaglio et al. 1999). 
The TALOS program uses the amino acid sequence information and chemical shift 
values of Cα, Cβ, C', Hα and 15N to search its database for similar amino acid triplets 
with the closest similarity in secondary chemical shifts and amino acid sequence. 
When TALOS identifies a high similarity in the database, it will predict the torsion 
angles phi and psi for that particular residue. Chemical shifts of Cα, Cβ, Hα and 15N 
of DCD1L obtained from the 3D experiments were used for the prediction in TALOS. 
The obtained torsion angle information (phi and psi) for each region, with well-
defined secondary structure were used for the structural calculation.  
3.3.3.5       NOE assignment and structural calculation 
NOE assignment was obtained from 3D 
15





N-edited NOESY was used to obtain the NOEs among the side-chain 
protons and the backbone amides. The 
13
C-edited NOESY experiment was used to 
obtain NOEs among side-chain-to-side-chain protons.  A total of 607 unambiguous 
NOEs were obtained from 3D 
15
N-edited NOESY and 3D 
13
C-edited NOESY.  The 
connectivities of the short range and medium range NOEs as well as the relative NOE 
intensities are shown in Figure 3.11 A. Most of the NOEs assigned were intraresidue 
NOEs and sequential NOEs. No long range NOE was observed. The NOEs 
dαβ(i,i+3), dαN(i,i+4), dαN(i,i+3), and dNN(i,i+2) are generally observed for the α-
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helices. They were observed in three parts of DCD1L including the N-terminal region 
from the residue Ser-2 to Leu-18, middle region from Lys-20 to Glu-30 and C-
terminal region from Gly-33-Leu-47. This result suggested that the 3 regions could 
adopt α-helice structures. This result agrees with the CSI data (Figure 3.10) and CD 
data (Figure 3.7). 
607 NOE restraints (220 intraresidue, 240 sequential and 147 medium range) 
and 56 TALOS angle restraints were used to calculate the 3D structure of DCD1L 
using the CYANA 2.1 software (Herrmann, Guntert et al. 2002). Detailed statistics of 
the SDS bound DCD1L structure can be seen in Table 3.3. The refined structure has 
the target function of 1.8. The 20 lowest-energy structures with backbone and heavy 
atom R.M.S.D were 2.36 Å and 2.80 Å respectively. These were checked using 
Procheck-NMR (Laskowski, Rullmannn et al. 1996).  
In general, the 3D structure of SDS bound DCD1L consists of three α-helices 
regions including N-terminal region from the residue Ser-2 to Leu-18, middle region 
from Lys-23 to Glu-30 and C-terminal region from Gly-33-Leu-47 (Figure 3.11 E). 
This result agrees with the CSI data (Figure 3.10) which also suggests that DCD1L 
contains 3 α-helical regions. The three α-helical regions are connected by 2 turns 
consisting of residues from Leu-21 to Lys-23 and from Glu-30 to Gly-33. These two 
turns were further confirmed by the re-examination of the NOESY spectrum, in which 
no NOE pattern suggesting the formation of an α-helical secondary structure could be 
observed (Figure 11A). No interactions between the 3 α-helices were observed as no 







Figure 3.11 NOE intensities, connectivities and the solution structure of SDS bound 
DCD1L  
(A) Relative intensities and connectivities of NOEs, 
15
N-edited NOESY and 
15
C-edited 
NOESY. Superposition of 20 lowest energy structures for SDS bound DCD1L are 
shown in B, C, and D. (B) Superposition of residues 2-18 (R.M.S.D: 0.52 +/- 0.24 Å). 
(C) Superposition of residues 20-30 (R.M.S.D: 0.23 +/- 0.11 Å). (D) Superposition of 
residues 32-47 (R.M.S.D: 0.69 +/- 0.27 Å). The structures were analyzed using Molmol 
(Koradi, Billeter et al. 1996). 
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Table 3.3 Statistics of the 20 lowest-energy ensembles of DCD1L structure in 
SDS 
A. Restraints used for calculation  
Total NOEs 607 
   Intraresidues (i,j) 214 
   Interresidue, sequential (|i, j| = 1) 246 
   Interresidue, medium range (1< (|i-j| ≤ 5 )      147 
   Interresidue, long-range (|i-j| ≥ 5 0 
Dihedral angle restraints (φ, ψ) 65 
Hydrogen bond restraints 0 
B. Structure statistics  
    No. of distance violations of > 0.20 Å 2 
    No. of dihedral angle violations of > 4° 0 
    Max. dihedral angle violation (°)  3.5 
    Max. distance constraint violation (Å) 0.36 ± 0.007 
Average RMS deviation (Å):  
    Back bones (Full length)  2.36 +/- 0.88 
    Heavy atom (Full length) 2.80 +/- 0.85 
    Back bone atoms (residues 2-18) 0.52 +/- 0.24 
    Back bone atoms (residues 20-30) 0.23 +/- 0.11 
    Back bone atoms (residues 32-47) 0.69 +/- 0.27 
C. PROCHECK Ramachandran plot analysis (%)  
   Most Favored Regions (%) 96 
   Additional Allowed Regions (%) 4 
   Generously Allowed Regions (%) 0 
   Disallowed Regions (%) 0 
 
 
3.3.3.6       Comparison of DCD1L structures in SDS and in 50%TFE  
The 3D structure of SDS bound DCD1L obtained in this study is significantly 
different from the 3D structure of DCD1L in 50% TFE (Figure 3.13 A, B), solved by 
Jung et al (2010). SDS bound DCD1L has a higher α-helix content than DCD1L in 
50% TFE. Approximately 90% residues of SDS bound DCD1L adopt an α-helix 
structure with 3 defined α-helical regions (helix1: from Ser2 to Ser18, helix 2: from 
Lys23 to Glu-30, helix 3: from Gly33 to Val47). Meanwhile, only 38% residues of 
DCD1L in 50% TFE adopt an α-helix structure with 4 α-helix regions (helix 1: from 
Glu5 to Glu7, helix 2: from Gly10 to Lys12, helix 3: from Glu27 to Ser31, and helix 
58 
 
4: from Val37 to Val43) (Jung, Yang et al. 2010). This result agrees with both our CD 
data (Figure 3.13 C) and CD data (Figure 3.13 D) reported by Jung (2010) that shows 
that the α-helix content of DCD1L in SDS is significantly higher than that in 50% 
TFE.  
The most important difference between the SDS bound DCD1L structure and 
DCD1L structure in 50% TFE is the N-terminal region. The N-terminal (Ser2 to 
Leu18) of SDS bound DCD1L adopts a well-defined α-helix structure (Figure 3.13 
A). At the same time, it is very flexible and does not adopt a well-defined structure in 
50% TFE (Figure 3.13 B). This result also agrees with our CD data as the N-terminal 
peptide SSL25 adopts a well-defined α-helical structure in both SDS and POPG 
(Figure 3.7).  This result also indicates that SDS bound DCD1L structure is more 
useful for the study of the structure of the bacterial membrane bound DCD1L as the 
CD spectra of both SSL25 and DCD1L in SDS and POPG are very similar (Figure 
3.7).  
The surface diagram of DCD1L plotted by the software MOLMOL (Koradi et 
al., 1996) shows that DCD1L is highly charged (Figure 3.12). This is because the 
protein consists of a high proportion of both positive and negative charged residues. 
The charged residues were unevenly distributed throughout the DCD1L structure. The 
N-terminal helix is composed of predominantly positively charged residues. 
Meanwhile, the C-terminal helix is composed of predominantly negatively charged 
residues. The net charge of DCD1L is negative which is uncommon for most 
antimicrobial peptides. However, from the structure of DCD1L in SDS (Figure 3.12), 
it is easy to see that most of the negatively charge residues are distributed at the C-
terminal of DCD1L.  This negatively charge residue may not play an important role in 
59 
 
killing microorganisms. The reason is that the SSL25, which does not have the C-
terminal, still can kill as well as DCD1L (Schittek, Hipfel et al. 2001).  This result 
suggests that the N-terminal part of DCD1L plays a more important role in terms of 





Figure 3.12 Surface diagram of DCD1L 
A. Ribbon diagram of SDS bound DCD1L. B. Surface charge of structure of SDS 
bound DCD1L consisting of positive charges (blue), negative charges (red), and 







Figure 3.13 Comparison of DCD1L structures in SDS and 50% TFE 
(A) SDS bound DCD1L structure; (B) DCD1L structure in 50% TFE (adapted from study 
reported by Jung et al. 2010); (C) CD spectra of DCD1L in 50% TFE, 30 mM SDS and 5 
mM POPG; (D) CD spectra of DCD1L in 50% TFE, 30 mM SDS (adapted from study 
reported by Jung et al. 2010) 





3.3.4 3D structure SDS bound DCD1L and its mechanism of action 
In 2012, Paulmann and coworkers have proposed two possible models for the 
mechanisms of DCD1L (Figure 3.14 C, D). In their models, DCD1L was initially a 
random coil in a free form (Figure 3.14.A). Upon interaction with the bacterial 
membrane, DCD1L changed its structure from a random coil to an α-helix structure 
and aligned parallelly to the membrane surface (Figure 3.14.B). DCD1L could self-
aggregate and form two possible ion channel models C and D (Figure 3.14. C and D). 
In model C, Paulmann and coworkers proposed that as the length of DCD1L is twice 
as long as the thickness of lipid bilayer, each monomeric DCD1L molecule could 
form a helical hairpin and self-aggregate to form transmembrane channels (Figure 
3.14.C). In model D, Paulmann and coworkers proposed that only the N-terminal part 
of DCD1L self-aggregates and forms transmembrane ion channels; the C-terminal is 
exposed outside and aligns parallelly to the membrane surface (Figure 3.14. D). 
As discussed above, the structure of DCD1L in 50% TFE cannot be used to 
support any model proposed by Paulmann and coworkers, as it is very flexible. 
However, the structure of SDS bound DCD1L is well-defined and it supports model D 
proposed by Paulmann. From the surface charge diagram of SDS bound DCD1L 
(Figure 3.12), it can be seen that at N-terminal (Ser1-Lys20), the hydrophobic 
residues (Leu-3, Leu-4, Leu-8, and Val-15) are concentrated on one side of the N-
terminal helix, while the charged residues are distributed on the other side (Glu-5, 
Lys-6, Asp-9, Lys-12 and Lys-13). This result suggests that the hydrophobic side of 
the N-terminal helix could be buried inside the hydrophobic core of SDS micelles.  In 
the C-terminal (helices 2 and 3), all the positively-charged residues (Lys-34, Lys-41, 
and Lys-44) face down and all the negatively-charge residues (Asp-24, Glu-27, Asp-
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28, Glu-30, Asp-39, Asp-42, and Asp-45) faces up. This result suggests that the 
positively charged side of the C-terminal interacts with the negative head group of the 
bacterial membrane-mimicking model (SDS) and the negatively charged residues are 
repelled to the other side. These results suggest that the N-terminal could form a 
transmembrane channel with the hydrophobic side interact with the hydrophobic 
region of membrane and the charge side exposes to the center of the channel (model 
F, Figure 3.14 F). The C-terminal region containing helices 2 and 3 are exposed 
outside and align paralelly to the membrane surface, with the positively-charged 
residues facing downward to interact with the negatively-charged surface of the 
bacterial membrane (model F). The negatively charged residues face upward, away 
from the negative surface of the bacterial membrane (model F).   
Collectively, our structural data of SDS bound DCD1L supports model D 
proposed by Paulmann and coworkers (2012). However, in order to confirm that the 
N-terminal of DCD1L is buried inside the hydrophobic core of SDS or POPG bilayer, 
the C-terminal of DCD1L is exposed out side, hydrogen deuterium exchange 


















Figure 3.14 SDS bound DCD1L structural support antimicrobial activity model 
D proposed by Paulmann and coworkers (2012) 
(A) DCD1L was initially a random coil in free form. (B) Upon interaction with 
bacterial membrane; DCD1L changed its structure from a random coil to an α-helix 
and aligned parallel to the membrane surface. DCD1L could self-aggregate and form 
two possible ion channel models C and D. (C) Each monomeric DCD1L molecule 
could form a helical hairpin and self-aggregate to form ion channels. (D) Only the N-
terminal part of DCD1L self-aggregates and forms transmembrane ion channels, the 
C-terminal is exposed outside and aligns parallelly to the membrane surface (adapted 
from Paulmann et al. 2012). (E) Ribbon and surface charge diagram of SDS bound 
DCD1L. (F) Model of DCD1L forming transmembrane channels, which supports 





3.3.5 Solving the structure of DCD2 using NMR 








N labeled DCD2 was obtained by growing the bacteria on M9 minimal 
media with 
15
N ammonium chloride as the sole nitrogen source. The DCD2/SDS 
complex contains 1 mM peptide and 60-fold deuterated SDS (Cambridge Isotope 
Laboratories).  
 









N HSQC spectrum of DCD2 was acquired using a Bruker 800 MHz NMR 
machine at 20
o
C in 20 mM phosphate buffer, pH8.0, 100 mM NaCl, 60 mM SDS. 




N HSQC spectrum were well resolved 
and successfully assigned. 
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N HSQC spectrum of DCD2 was acquired 
using a Bruker 800 MHz NMR machine at 25 
o
C in 20 mM phosphate buffer, pH8, 50 
mM NaCl, 60 mM SDS. The obtained spectrum showed a good dispersion of amide 
peaks with most of them having similar intensities (Figure 3.15). DCD2 has 3 prolines 
(Pro 45, Pro 52 and Pro 59) which do not have amide protons and therefore would not 




N HSQC. Fifty-four peaks out of a theoretical fifty-six peaks 




N HSQC spectrum. The two missing peaks were later 
identified as Ser-1 and Ser-2. Both Ser-1 and Ser-2 are located at the N-terminal end 
of DCD2, which would not significantly affect structure calculation. By using 3D 
spectrums CC(CO)NH, HC(CO)NH and 
15
N-edited NOESY,  information about Ser-
1, Ser-2, Pro 45, Pro 52 and Pro 59 side chain chemical shift and NOEs were obtained 
and included in the final structure calculation.  Overall, 96% of DCD2 amide cross-




N HSQC spectrum were well resolved and successfully assigned. 
3.3.5.2       Chemical shifts assignment of DCD2 
Backbone chemical shifts of DCD2 were assigned using 3D HNCACB and 
CBCA(CO)NH . The process is explained in detail in Section 2.5.1.2.  
3.3.5.3       Chemical shift index (CSI) 
After completing the backbone assignment of DCD2, we utilized the 
experimental Cα and Cβ chemical shifts of all residues to determine the chemical shift 
index. The calculated chemical shift index of DCD2 can be used to determine its 
secondary structure and boundaries (Wishart and Sykes, 1994). Calculation of the 
chemical shift index is described in detail in Section 3.3.3.3. From the CSI plot 
(Figure 3.16), it can be seen that the DCD2 secondary structure is quite flexible. Only 
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the N-terminus of DCD2 (aa 2-29) showed an α-helice structure while the rest of the 




Figure 3.16 Chemical Shift Index of DCD2    
CSI of SDS bound DCD2 was generated using the chemical shift values of all Cα and Cβ 
extracted from 3D HNCACB and CBCA(CO)NH experiments. The secondary structure 
represented by the CSI plot is shown on top of the figure. The overall plot indicates that only the 
N-terminus (aa 2-29) of SDS-bound DCD2 can form an α-helix; the C-terminus (aa 29-59) is 




3.3.5.4       NOE assignment and structure calculation 
The NOE assignment of DCD2 was obtained from 3D 
15
N-edited NOESY and 
3D 
13
C NOESY experiments. A total of 564 NOEs was obtained, including 3D 
15
N 
edited NOESY and 3D 
13
C NOESY.  The connectivities of short range and medium 
range NOEs as well as relative NOE intensities are shown in Figure 3.17. Most of the 
NOEs assigned were intraresidue NOEs and sequential NOEs. No long range NOE 
was observed. The NOEs dαβ(i,i+3), dαN(i,i+4) dαN(i,i+3), and dNN(i,i+2), which 
are generally observed for α-helices, were observed in two parts of DCD2: the N-
terminal region from residue Ser-2 to Leu-18 and the middle region from Lys-20 to 
Leu-29. This result suggested that the two regions could adopt α-helice structures. 
Significantly fewer NOEs, especially interresidue NOEs, were observed in the C-
terminal region from Glu-30 to Pro-59. This result suggested that the C-terminus is 
very flexible. This result agrees with the CSI data (Figure 3.16) and CD data (Figure 
3.7). 






Total NOEs 564 
   Intraresidues (i,j) 241 
   Interresidue, sequential (|i, j| = 1) 235 
   Interresidue, medium range (1< (|i-j| ≤ 5 )      88 
   Interresidue, long-range (|i-j| ≥ 5 0 
Dihedral angle restraints (φ, ψ) 70 
Hydrogen bond restraints 0 
B. Structure statistics  
    No. of distance violations of > 0.20 Å 0 
    No. of dihedral angle violations of > 4° 0 
    Max. dihedral angle violation (°)  0 
    Max. distance constraint violation (Å) 0.28 ± 0.002 
Average RMS deviation (Å):  
    Back bones (Full length)  7.40 +/- 1.81  
    Heavy atom (Full length) 8.05 +/- 1.74 
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    Back bone atoms (residues 2-17) 0.13 +/- 0.13 
    Back bone atoms (residues 20-29) 0.30 +/- 0.18 
C. PROCHECK Ramachandran plot analysis (%)  
   Most Favored Regions (%) 94 
   Additional Allowed Regions (%) 6 
   Generously Allowed Regions (%) 0 
   Disallowed Regions (%) 0 
 
564 NOE restraints (241 intraresidue, 235 sequential and 88 medium range) 
and 70 TALOS angle restraints were used to calculate the 3D structure of DCD2 
using the CYANA 2.1 software (Herrmann, Guntert et al. 2002). Detailed statistics of 
the SDS bound DCD2 structure can be seen in Table 3.4. The 20 lowest-energy 
structures with backbone and heavy atom R.M.S.D were 7.40 +/- 1.81 Å and 8.05 +/- 
1.74 Å respectively. They were checked using Procheck-NMR (Laskowski, Rullmann 
et al. 1996).  
Overall, the 3D structure of SDS bound DCD2 consists of 2 α-helical regions 
including the N-terminal region from residue Ser-2 to Leu-17 and the middle region 
from Lys-20 to Leu-29 (Figure 3.17). This result agrees with the CSI data (Figure  
3.16) and CD data (Figure 3.7). Two α-helical regions are connected by 1 turn from 
Leu-18 to Lys-20. Different parts of the DCD2 do not interact with each other, as 















Figure 3.17 NOE intensities, connectivities, and the solution structure of SDS bound DCD2 
(A) Relative intensities and connectivities of NOEs 
15
N-edited NOESY and 
15
C-edited 
NOESY; (B) A ribbon diagram of SDS bound DCD2 (C) Superposition of residues Ser-2 to 
Gly-17 (RMSD:  0.13 +/-  0.13 Å); (D) Superposition of residues Lys-20 to Leu-29 (RMSD:  




3.3.6 Solving the structures of SSL25 and SSL29  
3.3.6.1       Sample preparation 
SSL25 and SSL29 were purchased from GL Biochem (Shanghai) Ltd. The 
peptides were chemically synthesized by the peptide synthesizer GL Biochem 
(Shanghai) Ltd and purified to > 95% purity using RP-HPLC. The peptides were used 
directly without further purification. NMR samples were prepared using 1mM 
peptides with 60 mM deuterated SDS (Cambridge Isotope Laboratories) in a sodium 
phosphate buffer (pH 7.40) with 5% D2O. 
 3.3.6.2       NMR experiments and structure calculations                                 
  All NMR experiments were performed at 298 K using a Bruker 800 NMR 
Spectrometer equipped with a cryogenic probe. Backbone and sidechain protons were 
obtained using 2D-TOCSY combined with 2D-NOESY. NOE cross-peaks were 
obtained using 2D-NOESY. The NMR data obtained was processed using NMRpipe 
and analyzed by Sparky. NMR structure calculations were performed using CYANA 
2.1 software. 
3D structure of SSL25 
325 NOE restraints (134 intraresidue, 115 sequential and 76 medium range) 
and 40 TALOS angle restraints were used to calculate the 3D structure of SSL25 
using the CYANA 2.1 software (Herrmann, Guntert et al. 2002). Detailed statistics of 
the SDS bound SSL25 structure can be seen in Table 3.5. The 20 lowest-energy 
structures with backbone and heavy atom R.M.S.D were 0.19 +/- 0.14 Å and 0.69 +/- 
0.13 Å respectively. They were checked using Procheck-NMR (Laskowski, Rullmann 
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et al. 1996). Overall, the 3D structure of SDS bound SSL25 consists of 1 α-helical 
region from residue Ser-2 to Gly-22.  
 





Total NOEs 325 
   Intraresidues (i,j) 134 
   Interresidue, sequential (|i, j| = 1) 115 
   Interresidue, medium range (1< (|i-j| ≤ 5 )      76 
   Interresidue, long-range (|i-j| ≥ 5 0 
Dihedral angle restraints (φ, ψ) 40 
Hydrogen bond restraints 0 
B. Structure statistics  
    No. of distance violations of > 0.20 Å 0 
    No. of dihedral angle violations of > 4° 0 
    Max. dihedral angle violation (°)  0 
    Max. distance constraint violation (Å) 0.24 ± 0.005 
Average RMS deviation (Å):  
    Backbone atoms (Full length)  0.19 +/- 0.14 
    Heavy atoms (Full length) 0.69 +/- 0.13 
C. PROCHECK Ramachandran plot analysis (%)  
   Most Favored Regions (%) 96 
   Additional Allowed Regions (%) 4 
   Generously Allowed Regions (%) 0 







Figure 3.18 NOE intensities and connectivities and the solution structure of SDS 
bound SSL25 
(A) Relative intensities and connectivities of NOEs from 2D NOESY. (B) 
Superposition of the 20 lowest energy structures for SDS bound SSL25 with RMSD:  






3D structure of SSL29 
352 NOE restraints (142 intraresidue, 126 sequential and 84 medium range) 
and 48 TALOS angle restraints were used to calculate the 3D structure of SSL29 
using the CYANA 2.1 software (Herrmann, Guntert et al. 2002). Detailed statistics of 
the SDS bound SSL29 structure can be seen in Table 3.6. The 20 lowest-energy 
structures with backbone and heavy atom R.M.S.D were 0.85 +/- 0.36 Å and 1.53 +/- 
0.37Å respectively. They were checked using Procheck-NMR (Laskowski, Rullmann 
et al. 1996). Overall, the 3D structure of SDS bound SSL29 consists of 2 α-helical 
regions including the N-terminal region from residue Ser-2 to Gly-16 and the C-
terminal region from Leu-21 to Asp-28 (Figure 3.19).  
 
Table 3.6 Statistics of the 20 lowest-energy ensembles of SSL29 structure in SDS 
A. Restraints used for calculation  
Total NOEs 352 
   Intraresidues (i,j) 142 
   Interresidue, sequential (|i, j| = 1) 126 
   Interresidue, medium range (1< (|i-j| ≤ 5 )      84 
   Interresidue, long-range (|i-j| ≥ 5 0 
Dihedral angle restraints (φ, ψ) 48 
Hydrogen bond restraints 0 
B. Structure statistics  
    No. of distance violations of > 0.20 Å 0 
    No. of dihedral angle violations of > 4° 0 
    Max. dihedral angle violation (°)  0 
    Max. distance constraint violation (Å) 0.21 ± 0.004 
Average RMS deviation (Å):  
    Backbone atoms (Full length)  0.85 +/- 0.36 
    Heavy atoms (Full length) 1.53 +/- 0.37 
C. PROCHECK Ramachandran plot analysis (%)  
   Most Favored Regions (%) 96 
   Additional Allowed Regions (%) 4 
   Generously Allowed Regions (%) 0 











Figure 3.19 NOE intensities and connectivities and the solution structure of SDS 
bound SSL29 
(A) Relative intensities and connectivities of NOEs from 2D NOESY. (B) 
Superposition of 20 lowest energy structures for SDS bound SSL29 with RMSD:  
0.60 +/- 0.20 Å. C: superposition of residues Ser-2 to Leu-18 (RMSD:  0.22 +/- 0.14 
Å). D: superposition of residues Leu-21 to Glu-27 (RMSD:  0.31 +/- 0.16 Å). The 





3.3.7 Structure comparison between SSL25, SSL29, DCD1L and DCD2 
The SSL25 and SSL29 sequences were derived from the N-terminal region of 
DCD1L (Figure 3.20). The structural data obtained suggested that SSL25, SSL29, and 
the N-terminal region of DCD1L adopted similar α-helical structures in SDS (Figure 
3.20). A small difference between the structure of SSL25 and the N-terminal region of 
DCD1L is that the helix region of SSL25 from Ser-2 to Gly-22 is a bit longer than the 
N-terminal helix of DCD1L from Ser-2 to Leu-18. The SSL29 and N-terminal region 
(aa 1-29) of DCD1L have similar structures as they both have 2 α-helical regions. A 
small difference between SSL29 and the N-terminal region (aa 1-29) of DCD1L is 
that the loop region separating the 2 α-helical regions of SSL29 are from Gly-16 to 
Leu-21, while the loop region separating the 2 α-helical regions of DCD1L’s N-
terminal region is from Leu-18 to Lys-23.   
The structure of DCD2 is significantly different from that of DCD1L (Figure 
3.20). The C-terminal region of DCD2 from Ser-31 to Pro-59 is very flexible. 
However, the C-terminal region of DCD1L from Lys-33 to Val-47 adopted a well-
defined α-helical structure.  The N-terminal region of DCD2 from aa 1 to 29 has a 
similar structural pattern compared to DCD1L and SSL29 as it also adopted an α-
helical structure and has a loop from Gly-16 to Lys-20. However, the α-helical 
content in this region is significantly less compared to SSL29 or the N-terminal region 
of DCD1L. As the N-terminal region of DCD2 has the same sequence as SSL29 and 
the N-terminal region of DCD1L, it is possible that the C-terminal region of DCD2 
affects the structure of the N-terminal region, which may interfere with the membrane 
binding ability of DCD2. This result agrees with our CD data (Figure 3.20), where 













3.3.8       Lipid binding studies of DCD peptides 
It is generally accepted that the mechanism of action of many AMPs lie in 
their ability to interact with the bacterial membrane (Taheri-Araghi and Ha 2007; Lee, 
Park et al. 2009; Schmidtchen, Ringstad et al. 2011). DCD peptides are known to 
interact with bacterial membranes (Li, Rigby et al. 2009; Jung, Yang et al. 2010). 
Therefore, we want to analyze the interaction affinity of DCD peptides with bacterial 
membranes using POPG vesicles as a bacterial membrane model.  
3.3.8.1       DCD peptides bind to POPG differently 
Titration of DCD peptides (SSL25, SSL29, DCD1L, DCD2) with different 
concentrations of POPG vesicles was performed using 20 µM of peptides for each 
sample. The Far-UV spectra were recorded as described in Section 2.4.1 and shown in 
Figure 3.21.A, B, C, D. From Figure 3.21 A-D, it can be seen that all four DCD 
peptides including SSL25, SSL29, DCD1L, DCD2 change their conformations from 
random coils to α-helix structures upon interaction with POPG vesicles. However, the 
α-helix content obtained is significantly different among the 4 peptides when the CD 
spectra are saturated. SSL25 and SSL29 (Figure 3.17 A, B respectively) have 
similarly high α-helix content, indicating that they can interact very well with POPG 
vesicles.   DCD1L also has a relatively high α-helix content. However, DCD2 has 
significantly lower α-helix content (Figure 3.21.C and D). These results agree with the 
structural data of SSL25, SSL29 and DCD1L solved in SDS (Section 3.3.7). The 3D 
structures of SSL25, SSL29 and DCD1L showed that they adopt a well-defined α-
helix structure in most parts of their molecules. Meanwhile half of DCD2 (C-terminal 
region of DCD2 from Glu-30 to Pro-59) exists as random coils. These results also 
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suggest that the structures of SSL25, SSL29 and DCD1L in SDS should be similar to 
those in POPG vesicles.  
From the CD saturation curve of DCD peptides/POPG interaction (Figure 
3.22), it can be seen that the structure changes of SSL25 and SSL29 saturated at 
similarly low concentration of POPG with the dissociation constant of 0.112 mM and 
0.145 mM respectively. The dissociation constants of DCD1L and DCD2 are 2.92 
mM and 0.354 mM respectively, suggesting that DCD1L and DCD2 do not bind 
POPG as well as SSL25 and SSL29 do. As SSL25 and SSL29 are in the N-terminal 
region of DCD1L or DCD2 (from 1 to 25 and 29 respectively), it is likely that the C-
terminal regions of DCD1L (Glu-30 to Leu-48) and DCD2 (Glu-30 to Pro-59) do not 
bind to POPG vesicles or bind with very low affinity.  
  
Figure 3.21 CD titration of DCD peptides (A) SSL25, (B) SSL29, (C) DCD1L, (D) DCD2 with 






Figure 3.22 Dissociation constant of DCD peptides/POPG interaction 
Curve fitting and dissociation constant (Kd) determination for interaction of SSL25 
(A), SSL29 (B), DCD1L (C) and DCD2 (C) with POPG vesicles. All data was 





3.3.8.2       C-termini of DCD1L and DCD2 do not bind to POPG 
In order to identify which parts of the DCD peptides are important for lipid 
binding ability, different DCD peptide fragments were analyzed. As we have already 
shown in Section 3.3.2, SSL25 and SSL29 can bind to POPG very well, which means 
that the N-terminal parts (aa 1-29) of DCD1L and DCD2 are important for POPG 
binding. We also wanted to test whether the C-termini of DCD1L and DCD2 are 
important for POPG binding. DCD1L C-terminal (aa 30-48) and DCD2 C terminal 
(aa 30-59) are chemically synthesized by GL Biochem Ltd with 95% purity. The 
binding of these peptides to POPG vesicles was analyzed by Far UV CD. From Figure 
3.2 A, it can be seen that the DCD1L C-terminus exist as a random coil in phosphate 
buffer (pH7.4). Its secondary structure does not change in the presence of up to 2.4 
mM POPG. This result indicates that either the DCD1L C-terminal does not bind to 
POPG vesicles or the binding does not induce the change in secondary structures. 
This result suggests that DCD1L needs the N-terminus in order to bind to POPG 
From Figure 3.23 B, it can be observed that the DCD2 C-terminal also exists 
as random coils in phosphate buffer (pH7.4). It does not change its secondary 
structure in the presence of 2.4 mM POPG. This result also indicates that either the 
DCD2 C-terminus does not bind to POPG vesicles or the binding does not induce the 
change in secondary structure of the peptide. This result agrees with the structure of 
DCD2 as the structure in a bacterial membrane mimicking environment (SDS) shows 
random coils at the C-terminal region (aa 30-59). 







Figure 3.23 C-termini of DCD1L and DCD2 do not bind to POPG 
(A) CD titration of DCD1L C-terminal (30-48) with POPG vesicles; (B) CD titration 




3.3.9. Antimicrobial activity of DCD peptides  
SSL25 and DCD1L are known to kill a broad spectrum of Gram-positive and 
Gram-negative bacteria (Schittek, Hipfel et al. 2001). SSL29, which contains only 
four more aa (VEDL) at the C-terminus compared to SSL25, does not have 
antimicrobial activity (Schittek, Hipfel et al. 2001). Antimicrobial activity in DCD2 
has not been reported in any publication so far. In this study, we want to test the 
antimicrobial activity of SSL25, SSL29, DCD1L and DCD2 against various bacterial 
strains using colony count assays as described by Schittek and coworkers (2001, 
2006). It is very surprising to us that none of the DCD peptides showed antimicrobial 
activity against Gram-positive bacteria B.megaterium, S. aureus and Gram-negative 
bacteria E. coli, P. aeuroginosa in 10 mM sodium phosphate buffer (pH7.0) without 
salt (Figure 3.24). No antimicrobial activity was observed when the buffer was added 
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+
) 
ions. The DCD peptides did not show any antimicrobial activity against E. faecalis 









 ions. The radial diffusion assay method also showed that 
DCD peptides have no antimicrobial activity (data not shown). In addition, we tested 
antimicrobial activity of the DCD peptides using the broth microdilution method. The 
DCD peptides showed no antimicrobial activity against B. megaterium, S. aureus, 
E.coli and P.aeuroginosa in the presence of Ca
2+
 (Table 3.7) and Mg
2+
 (Table 3.8).  
Collectively, in this study, the DCD peptides did not show any antimicrobial 
activity against various microorganisms including B. megaterium, S. aureus, E.coli, 
P.aeuroginosa E. faecalis and C.albicans. This result contradicts the results reported 
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by Schittek and coworkers (Schittek, Hipfel et al. 2001). All positive controls, 
including LL37, reduced human beta defense-3 and recombinant RNase7 showed 
good antimicrobial activity, indicating that the experiments were done properly. These 
results suggest that DCD peptides may need special conditions, which have not been 
reported, in order to show antimicrobial activity. Despite the fact that DCD peptides 
did not show any antimicrobial activity, the CD data of DCD1L obtained in our study 
agree with data reported by Paulman, Schittek and coworkers (2012) as well as data 
reported by Jung and coworkers (2010). This suggests that our lipid binding studies 




Figure 3.24 Antimicrobial activity of DCD peptides against bacteria in the 





The antimicrobial activity of DCD peptides obtained from the broth 
microdilution assay is showed below:  
Table 3.7 Antimicrobial activity of DCD1L against bacterial strains in the 
presence of 10µM Ca
2+
 
DCD1L Concentration (µg/ml) BM1 BM2 EC1 EC2 PA1 PA2 SA1 SA2 
Positive control 
 (100g/ml LL37)   
- - - - - - - - 
Positive control 
 (reduced HBD-3)   
- - - - - - - - 
Positive control 
 (rRNase7)   
- - - - - - - - 
500 + + + + + + + + 
200 + + + + + + + + 
100 + + + + + + + + 
50 + + + + + + + + 
10 + + + + + + + + 
Growth control + + + + + + + + 
 
Table 3.8  Antimicrobial activity of DCD1L against bacterial strains in the 
presence of 10µM Mg
2+ 
DCD1L Concentration (µg/ml) BM1 BM2 EC1 EC2 PA1 PA2 SA1 SA2 
Positive control 
 (100g/ml LL37)   
- - - - - - - - 
Positive control 
 (reduced HBD-3)   
- - - - - - - - 
Positive control 
 (rRNase7)   
- - - - - - - - 
500 + + + + + + + + 
200 + + + + + + + + 
100 + + + + + + + + 
50 + + + + + + + + 
10 + + + + + + + + 
Growth control + + + + + + + + 
 
Abbreviations for table 3.7 and 3.8: BM (Bacillus megaterium), EC (Escherichia coli), PA 
(Pseudomonas auroginosa) and SA (Staphylococcus aureus). The numbers 1 and 2 stand 
for their duplication. The  presence  or  absence  of visible bacterial growth after overnight 
incubation at 37
o
C were illustrated as (+) or (-), respectively. Positive controls are 
cathelicidin (LL37), reduced human beta defensin-3 (rHBD-3) and recombinant RNase7. 






Dermcidin (DCD) is a human antimicrobial peptide, which shows a broad spectrum 
of antimicrobial activities against a variety of pathogenic microorganisms, including Gram-
positive, Gram-negative bacteria, fungus and even drug-resistant S. aureus, rifampin- and 
isoniazid-resistant Mycobacterium tuberculosis (Schittek, Hipfel et al. 2001). DCD plays an 
important role in maintaining the human skin barrier. A deficiency in DCD peptides is 
thought to impair the skin barrier of patients with AD (Rieg, Steffen et al. 2005). Although 
DCD shares similar antimicrobial activities with other antimicrobial peptides, it has no 
sequence homologous to other known antimicrobial peptides and seems to be unique. Its 
specific method of killing microbes is still unknown to date.  
The structure of DCD1L in TFE was solved in 2010 (Jung, Yang et al. 2010). 
However, this structure cannot explain the mechanism of action of DCD. In this study, four 
different fragments of DCD peptides, (DCD1L, SSL29, SSL25 and DCD2) carrying distinctly 
different charges and isoelectric points (pI) were chosen for structural study to deduce their 
antimicrobial mechanisms. The 3D structures of DCD peptides, including SSL25, SSL29, 
DCD1L and DCD2, were solved in the presence of 60 mM SDS. The structure supports one 
of the models for DCD’s mechanism of action proposed by Schittek and coworkers. We also 
discovered that the N-terminus of DCD1L (Ser-1 to Leu-29) has high interaction affinity with 
bacterial membrane model (POPG). Meanwhile the C-terminus of DCD1L (Glu-30 to Leu-
48) is not likely to interact with POPG.  DCD peptides did not show any antimicrobial 
activity in our study. However, the CD data of DCD1L obtained in our study agrees 
with data reported by Paulman, Schittek and coworkers (2012) as well as data 
reported by Jung and coworkers (2010). This suggests that our studies on lipid 




CHAPTER 4.   THE INTERACTION OF NF-κB (P50 AND P65) WITH THEIR 
SMALL INHIBITORS 
4.1    SUMMARY 
NF-κB is a transcription factor that controls over 500 genes and plays a key 
role in regulating the human immune system. NF-κB dysregulation is associated with 
many human diseases, including atopic dermatitis. In this study, we examined the 
interaction between the two most dominant NF-κB (p50 and p65) and their inhibitors, 
andrographolide and parthenolide. We mapped the binding site of andrographolide on 
p50 and determined the interaction efficacy of andrographolide and its derivatives 
with p50. The interaction efficacy levels of helenalin and parthenolide with p65 were 
also characterized. We discovered that parthenolide can interact with p50 through 
Cys-62 and inhibit p50/DNA binding. The knowledge obtained from our study can 
contribute to the designing of better drugs to regulate the NF-κB pathway and cure 
atopic dermatitis, as well as other NF-κB related diseases.  
4.2    INTRODUCTION 
4.2.1       NF-κB proteins 
 NF-κB is a transcription factor which was first discovered by Sen and 
Baltimore in 1986. The name NF-κB is an abbreviation of its full name, Nuclear 
Factor kappa-light-chain-enhancer of activated B cells. NF-κB is found in almost all 
types of animal cells (Gilmore 2006). It plays a central role in regulating the 
immune system (Brasier 2006; Gilmore 2006; Perkins 2007; Vallabhapurapu and 
Karin 2009). It controls up to 500 genes involved in immune responses (Liang, 
Zhou et al. 2004; Vallabhapurapu and Karin 2009) and also coordinates both innate 
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and adaptive immunity (Bonizzi and Karin 2004). NF-κB participates in cellular 
responses to diverse stimuli such as stress, cytokines, free radicals, ultraviolet 
radiation, and bacterial or viral antigens (Brasier 2006; Gilmore 2006). Incorrect 
regulation of NF-κB has been linked to a number of human diseases such as cancer, 
inflammatory and autoimmune diseases, septic shock, viral infection, and improper 
immune development (Giuliani, Napolitano et al. 2001; Feinman, Siegel et al. 
2004). 
In humans, there are five NF-κB transcription factors including NF-κB1 
(p50), NF-κB2 (P52), RelA (p65), RelB and c-Rel (Gilmore 2006; Perkins 2007). 
They are categorised in two subfamilies: the NF-κB proteins (NF-κB1 or p50, 
NF-κB2 or p52) and the Rel proteins (RelA or p65, RelB and c-Rel). All five NF-
κB members contain a DNA-binding domain called the Rel homology domain 
(RHD) in their N-terminus (Figure 4.1). These DNA-binding domains are 
structurally and functionally conserved from the fruit fly to humans (Wolberger 
1998; Brasier 2006). 
 
Figure 4.1 Members of the NF-κB family (Adapted from Perkins, 2007) 
RHD: Rel homology domain; TA/TAD: transcriptional activation domain; ANK: 





The NF-κB subfamily, which consist of the NF-κB1 and NF-κB2 proteins, 
are expressed as large precursors P105 and P100 respectively. These precursors 
contain a long domain (ANK domain) with several ankyrin repeats at the C-
terminus. These ANK domains act to inhibit the proteins. Upon either limited 
proteolysis or arrested translation, P105 and P100 undergo processing to generate 
shorter mature NF-κB proteins p50 and p52 respectively. All members of the Rel 
subfamily including c-Rel, RelB, and RelA (p65), contain a transcriptional 
activation domain (TA/TAD) at the C-terminus. These TA domains activate the 
transcription of genes in dimeric forms. 
Almost all NF-κB proteins can form homodimers or heterodimers. However, 
members of the NF-κB subfamily can activate transcription only when they form 
heterodimers with members of the Rel subfamily (Li and Verma 2002).  Among all 
homo- and hetero-dimers of NF-κB proteins, the p50/p65 heterodimer is the most 
predominant form, which is ubiquitous in all cell types. The expression of p52 is 
found in epithelium, macrophages, lymphocytes, and dendritic cells. The RelB 
expression is found in dendritic cells and lymphocytes while expression of c-Rel is 
restricted to haematopoietic cells (Magne, Toillon et al. 2006). There is a lot of 
evidence to suggest that the different forms of NF-κB may activate different sets of 
target genes (Barnes and Larin 1997). 
4.2.2       NF-κB pathways  
  In unstimulated cells, NF-κB dimers are maintained in an inactive state in the 
cytoplasm by the formation of complexes with their inhibitors, IκBα (Gilmore 2006). 
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Upon diverse stimuli such as stress, cytokines, free radicals, ultraviolet radiation and 
bacterial or viral antigens, the trimeric IκB kinase (IKK) complex is activated. The 
activated IKK complex phosphorylates IκBα on Ser-32 and Ser-36. Phosphorylated 
IκBα is then ubiquitinated at Lys-19 by an ubiquitin ligase complex. The 
ubiquitinated IκBα is then recognized and degraded by the 26S proteasome. After 
IκBα is degraded, the nuclear localization signals of NF-κB proteins are exposed. 
This induces the translocation of NF-κB dimers to the nucleus. In the nucleus, NF-
κB dimers recognize and bind to κB sites (5’-GGGPuNPyPyPyCC-3’, where 
Pu = purine, N = any nucleic acid, Py = pyrimidine). The binding of NF-κB 








4.2.3       Role of the NF-κB pathway in inflammatory diseases 
Growing evidence has demonstrated that the NF-κB activation plays a 
pivotal role in the initiation and development of inflammatory diseases 
including atopic dermatitis (Barnes and Larin 1997; Yamamoto and Gaynor 2001; 
Nakamura, Aoki et al. 2002). NF-κB may exacerbate inflammation through its 
ability to induce the production of many cytokines and chemokines as well as 
enzymes and adhesion molecules, which are involved in inflammatory responses 
(Barnes and Larin 1997; Tanaka, Kyoungsook et al. 2007). The expression of 
nitric oxide synthase, an enzyme regulated by NF-κB, was increased in the 
colonic epithelial cells of ulcerative colitis patients (Xie, Kashiwabara et al. 
1994). The expression of nitric oxide synthases was also increased in airway 
epithelial cells and macrophages of asthma patients and in the synovial cells of 
patients with inflamed joints (Hamid, Springall et al. 1993; Evans, 
Stefanovicracic et al. 1995).  
The expression of cyclooxygenase-2, another enzyme regulated by NF-κB, 
was increased in patients with rheumatoid arthritis (Crofford, Wilder et al. 1994). 
The increased expression of cyclooxygenase-2 led to an increased production of 
prostaglandins and thromboxane which are known to be involved in inflammatory 
response (Crofford, Wilder et al. 1994; Barnes and Karin 1997). NF-κB also 
regulates the production of adhesion molecules such as intercellular adhesion 
molecule 1, vascular-cell adhesion molecule 1, and E-selectin. These molecules are 
involved in inflammation by recruiting inflammatory cells to the site of inflammation 
(Albelda, Smith et al. 1994). The continuous activation of NF-κB was known to 
result in the increased transcription of pro-inflammatory proteins in both bronchial 
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biopsies and inducing sputum in patients with asthma (Sidebotham and Roche 2003; 
Caramori, Adcock et al. 2004; Caramori, Oates et al. 2009). Many genes involved in 
inflammatory diseases, such as IL-9, IL-13, eotaxin, TSLP, ICAM-1, VCAM-1, E-
selectin, etc, are known to be regulated by NF-κB as they contain κB sites within 
their promoters (Ahn and Aggarwal, 2005).  
Numerous NF-κB inhibitors such as IKKβ inhibitors, IκB degradation 
inhibitors, the NF-κB-specific decoy oligonucleotide and the p65-specific antisense 
oligonucleotide, have shown positive effects in inflammatory diseases. (Birrell et al., 
2005; Desmet et al., 2004; Ziegelbauer et al., 2005). This suggests that the inhibition 
of NF-κB pathways is a promising strategy for the treatment of inflammatory 
diseases. 
4.2.4       Inhibition of NF-κB pathway 
NF-κB is involved in many cellular processes. Constitutive activation or 
dysregulation of NF-κB has been linked to numerous human diseases such as cancer, 
diabetes, atopic dermatitis, AIDS, etc. Therefore, numerous NF-κB-pathway 
inhibitors have been developed for the treatment of these diseases, especially in the 
case of inflammatory diseases and cancer where the NF-κB pathway is constitutively 
activated. So far, more than 700 NF-κB-pathway inhibitors have been characterized 
(Gupta, Sundaram et al. 2010). Different steps of the NF-κB pathway were targeted, 
including stimulation, IKKs activation, IκB phosphorylation, IκB degradation, and 
NF-κB/DNA binding steps (Pande and Ramos 2005; Gilmore 2006; Gupta, 
Sundaram et al. 2010). 
Inhibitors targeted at the stimulation step are mainly antioxidants such as 
glutathione, α-lipoic acid and pyrrolidine dithiocarbamate. These antioxidants act by 
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scavenging free radicals generated by stimuli such as UV and stress, and thus prevent 
the activation of the NF-κB pathway. Antioxidants have limitations as they also 
interact with other protein targets (Pande and Ramos 2003; Pande and Ramos 2005).  
Another group of NF-κB pathway inhibitors (including aspirin, 
hydroxyquinone and monochloramine) targets the IκB phosphorylation step. These 
inhibitors inhibit the IKK complex, which is responsible for the phosphorylation of 
IκB, thus inhibiting the activation of NF-κB. These inhibitors have limitations, as 
they could interfere with other kinases in cells.  
After IκB is phosphorylated, it is then ubiquitinated and degraded by the 26S 
proteasome. Many NF-κB pathway inhibitors are also developed to interfere with 
IκB degradation by inhibiting the 26S proteasome. However, the 26S proteasome is 
involved in many other protein degradation processes. Therefore inhibiting the NF-
κB pathway through 26S proteasome inhibition also has limited value as it may cause 
side effects. 
The inhibition of the NF-κB pathway by inhibiting NF-κB/DNA binding is 
considered the best option for research on drug discovery, which is described in 
detail in the next section.  
4.2.5       Inhibition of NF-κB/DNA binding 
The specificity of inhibition is one of the most important criteria for drug 
design. In the NF-κB pathway, inhibitors that selectively target the NF-κB/DNA 
binding step can achieve the highest level of specificity. Therefore, inhibitors 
targeting the NF-κB/DNA binding step have attained great attention recently (Pande, 
Sharma et al. 2003; Pande and Ramos 2005).  
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Decoy oligodeoxynucleotides (ODNs) are a notable group of NF-κB/DNA 
binding inhibitors.  These ODNs have a κB site, which can compete and bind to NF-
κB dimers, thus preventing NF-κB dimers from binding to specific promoters 
(Morishita, Sugimoto et al. 1997; Khaled, Butfiloski et al. 1998). These ODNs are 
modified to be more stable with a higher affinity for NF-κB in vivo (Tomita, Ogihara 
et al. 2003). ODNs have shown beneficial effects in many animal models of various 
diseases including atopic dermatitis (Dajee, Muchamuel et al. 2006). However, these 
ODNs still have several limitations including low bioavailability, short half-life, and 
limited intracellular uptake (De Stefano, De Rosa et al. 2010). 
Many NF-κB/DNA binding inhibitors have ability to directly modify the 
redox regulated cysteine residues of NF-κB, thus preventing NF-κB from binding to 
specific DNA (Pande, Sousa et al. 2009; Gupta, Sundaram et al. 2010). These redox 
regulated cysteine residues are Cys-62 of p50 and Cys-38 of p65 (Figure 4.3). NF-
κB/DNA binding inhibitors can interact with redox regulated cysteine residues in 
different mechanisms including (a) S-thiolation, (b) S-nitrosylation and (c) 
irreversible covalent modification. Some important inhibitors which were designed 
based on S-thiolation, S-nitrosylation and irreversible covalent modification 
(alkylation) and their target cysteine residues are listed in Table 4.1. However, the S-
thiolation and S-nitrosylation based NF-κB inhibitors have a significant limitation: 
they are less specific. In addition, reducing proteins such as Thioredoxin and 
glutaredoxin can reverse S-thiolation and S-nitrosylation of the cysteines. 
The inhibitors that can form irreversible covalent bonds with the NF-κB 
protein are the most promising (Gupta, Sundaram et al. 2010). These inhibitors are 
alkylating agents which are reportedly able to interact with the critical cysteine 
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residue of α,β-unsaturated aldehydes (Uchida 2000; Sayre, Smith et al. 2001). Some 
well-studied alkylation-based NF-κB inhibitors are listed in Table 4.1, including 
cyclopentenone prostagrandin J2, sesquiterpene lactones (helenaline/parthinolide), 
kamebakaurin, cryptolepine, epoxyquinone A, herbimycin A and andrographolide.  
Cyclopentenone prostagrandin J2, kamebakaurin, herbimycin A and andrographolide 
are known to specifically interact with Cys-62 of p50. Sesquiterpine lactones and 
epoxyquinone A are reported to selectively interact with Cys-38 of p65. Cryptolepine 
is proposed to interact with both Cys-62 of p50 and Cys-38 of p65. Despite the fact 
that the interacting targets of these inhibitors are known, the mechanism of action is 
still unclear. The factors that affect the selectivity of these inhibitors are still 
unknown.  More importantly, none of these inhibitors have been approved clinically 
thus far, indicating that more work needs to be done in order to develop them into 


















Table 4.1 Summary of important NF-κB inhibitors, which form direct covalent 










Figure 4.3 Crystal structure of p50-p65 heterodimers and proposed interaction 
sites of NF-κB/DNA binding inhibitors 
 
4.2.6       Andrographolide (Andro) 
Andro is the most active compound isolated from a Chinese herbal plant 
named Andrographis paniculata. Prior research has documented various anti-
inflammatory activities of andro (Moncada, Higgs et al. 1997; Marshall and Stamler 
2001). Recent studies have shown that andro attenuates inflammation by inhibiting 
NF-κB activation. Andro can form a covalent bond with Cys-62 of p50, which 
inhibits NF-κB activation and prevents the activation of pro-inflammatory and 
inflammatory genes such as iNOS, COX-2, E-selectin, and VCAM-1 (Uchida 2000; 
Sayre, Smith et al. 2001). Although andro has shown therapeutic potential for 
treatment of inflammatory diseases such as atopic dermatitis and asthma, andro has 
relatively high toxicity. 
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Andro inhibits NF-κB activation by forming a covalent bond with the critical 
Cys-62 of p50 (Xia, Ye et al. 2004). However, its mechanism of action is still not 
clearly understood. Pande et al, 2009 have suggested that andro contains an 
exomethylene group (C8=C17, Figure 4.4), which can modify Cys-62 of p50 by 
Michael addition. Zhang et al (2008) and Yao et al (2012) have both proposed an 
alternative mechanism of action of p50/andro alkylation. Zhang and his colleagues 
tested the interaction of andro with GSH and showed that the α,β-unsaturated lactone 
moiety of andro can react with the SH group of GSH through Michael addition 
(Zhang, Chan et al. 2008). Yao and his colleagues observed a similar result when 
they let 14-α-Lipoic acid-3,19-dihydroxyandrographolide interact with the SH group 
of GSH (Yao, Li et al. 2012). Zhang and Yao used GSH as a p50 model, which may 
not be absolutely correct as GSH is a small molecule and the p50 protein is a 
macromolecule. Moreover, the mechanism of action proposed by Zhang and his 
colleagues suggest that andro can interact with all exposed cysteine residues. This 
cannot explain why andro can selectively interact with Cys-62 of p50 but not with 
Cys-38 of p65 (Pande, Sousa et al. 2009).  
 
Figure 4.4 Andrographolide (andro) 
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4.2.7       Sesquiterpine Lactones 
Sesquiterpene lactones (SLs) are a large group of secondary plant 
metabolites. So far, more than 5000 SLs have been discovered. They possess not 
only anti-inflammatory activity but also a broad range of other biological activities 
such as antitumour, antibacterial, antimalarial activities. Helenalin and parthenolide, 
two well-known sesquiterpene lactones, have been reported to form a covalent bond 
with Cys-38 of P60, resulting in the inhibition of NF-κB activation (Garcia-Pineres, 
Castro et al. 2001; Zhang, Won et al. 2005). Similar to andro, SLs also have α,β-
unsaturated carbonyl structures, which is thought to react with the sulfhydryl groups 
of cysteines in a Michael addition. However, the mechanism of action of SLs 
interacting with Cys-38 of p65 is not clearly understood.  
Schmidt and his colleagues (1999) have proposed a model, showing that 
helenalin can interact with the SH group of GSH, which may be used as a model for 
p65/SLs interaction (Schmidt, Lyss et al. 1999). Schmidt and his colleagues used 
GSH as a p65 model, which may not be absolutely accurate as GSH is a small 
molecule and p65 protein is a macromolecule. Moreover, the mechanism of action 
proposed by Schmidt and his colleagues suggest that SLs can interact with all 
exposed cysteine residues. However, this cannot explain why SLs can selectively 
interact with Cys-38 of p65 but not with Cys-62 of P50 (Pande, Sousa et al. 2009). 
SLs are interesting research compounds and have the potential for therapeutic 
applications (Merfort 2011). SLs, including helenalin and parthenolide, have 
significantly high cytotoxicity against normal cells that limit its potential to be used 
in the creation of safe and potent drugs. However, parthenolide and helenalin can be 
used as lead compounds to design potent NF-κB inhibitors with increased specificity 





Figure 4.5 Chemical structure of parthenolide 
 
4.3 OBJECTIVES 
Constitutive activation of NF-κB is responsible for the initiation and 
development of inflammatory diseases, including atopic dermatitis (Barnes and Larin 
1997; Yamamoto and Gaynor 2001; Nakamura, Aoki et al. 2002).  Therefore, the 
development of specific NF-κB inhibitors is promising for attenuating inflammatory 
diseases such as Alzheimer’s disease and asthma. Andro and sesquiterpine lactones 
(helenalin and parthenolide) are interesting lead compounds to design specific NF-κB 
inhibitors. However, the mechanisms of action of these compounds are not clearly 
understood. The objectives of this study are listed below:  
 Identify the possible binding site of andro to p50 
 Study the mechanism of action of andro and its derivatives to p50 
 Study the interaction efficacy of andro and its derivatives with p50 
 Study the effect of reducing agents on the p50/andro interaction 
 Study the interaction of parthenolide and helenalin with p65 and p50 
The results obtained from this study could help to develop specific NF-κB 
inhibitors with high potency and specificity and minimal side effects. 
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4.4    RESULTS AND DISSCUSSION 
4.4.1       Semi-quantification of the p50-andro interaction by ESI-Qtof 
Interaction efficiency between andro and p50 was determined using a protocol 
described in Section 2.6.2. Briefly, andro was added to p50 solution with different 
molar ratios of andro-to-p50 from 0, 2, 4, 8, 10 20, to 50. For each sample, 1 ml of 
p50 (20 µM) was incubated with andro at 37
o
C for 2 h.   The samples were purified 
using a reverse-phase column (Atlantis, dC18, 4.6x250 mm, 5 μm, Waters). Purified 
samples were analyzed using a Synapt HDMS mass spectrometer (Waters, 
Manchester, UK).  
From Figure 4.6, it can be seen that andro/P50 interaction can be detected 
easily using ESI-Qtof.  The mass of apo p50 (38335) shifts 332 Da as andro forms a 
covalent bond with p50. The amount of andro/p50 complex formed increases when 
the molar ratio of andro/p50 increases. Almost all p50 proteins form complexes with 
andro when the molar ratio of andro/p50 reaches 10 to 1. Many studies have reported 
the covalent interactions between p50 and its ligands, yet no study has ben conducted 
on the interaction affinity of p50 with its ligands. This is the first report showing the 
interaction efficacy of p50 with its covalent modification inhibitor. This result 
indicates that this method can be used to determine interaction efficacy of not only 
p50 with andro, but also p50 or P65 with many other covalent modification ligands. It 










      
Figure 4.6 p50-andro interaction monitored by ESI-Qtof 
The mass of apo p50 (38335 Da) shifts 332 Da as andro forms a covalent bond with 
p50. The amount of andro/p50 complex formed increases when the molar ratio of 
andro/p50 increases. Most apo p50 was converted to andro/p50 complex when the 






4.4.2       Identifying the possible binding site of andro with p50 
4.4.2.1       Docking of andro on p50  
In order to identify the possible binding site of andro on p50, the crystal 
structure of NF-κB p50 (PDB ID: 1NFK) was used for docking with andro. The 
docking was done using the program Autodock 4.0 (Morris, Goodsell et al. 1998) as 
mentioned in detail in Section 2.6.1. The results obtained (Figure 4.7) showed that 
andro was docked in a cavity surrounded by V61, C62, S66, V115, N139, I142, L143. 
In order to confirm whether this cavity was the possible binding site of andro, single 
mutants V61A, C62A, S66A, V115A, N139A, I142A, L143A were generated 
(Section 2.2.8). These mutants were then used to test whether they could affect the 












4.4.2.2       Expression of p50 and its mutants 
A DNA insert of p50 Rel homology domain (aa 39-364), a gift from Prof. G. 
Ghosh (University of California, San Diego), was subcloned into a pET-M expression 
vector and subsequently transformed into E. coli BL21(DE3) cells for protein 
expression. P50 mutants (V61A, C62A, S66A, V115A, N139A, I142A, L143A) were 
generated by the method described in Section 2.2.8. P50 and its mutants (V61A, 
C62A, S66A, V115A, N139A, I142A, L143A) were expressed using the method 
described in Section 2.3.1. 
From Figure 4.8 A, it can be seen that recombinant p50 can be expressed at 
high levels. Approximately 50 mg of recombinant p50 was obtained from 1 L of LB 
medium. P50 single mutants V61A, C62A, S66A, V115A, N139A, I142A, L143A 
were also expressed at high level and purified with purity close to homogeneity 
(Figure 4.8 B). These recombinant proteins were then tested to confirm whether they 






Figure 4.8 Expression of NF-κB p50 and its mutants 
A: Expression of p50. B: Expression and purification of p50 single mutants V61A, 





4.4.2.3       Biophysical characterisation of p50 and its mutants 
a.        CD of p50 and its mutants 
In order to confirm that the expressed p50 and mutants were folded properly, 
the proteins were analyzed using CD (Section 2.4.1). From the CD spectrum of p50  
(Figure 4.9), it can be seen that p50 has a negative peak at around 205 nm and a 
negative peak at 222 nm indicating that the p50 has an α-helix structure. The negative 
peak at 205 nm is much deeper than the negative peak at 222 nm, which suggests that 
p50 also has a β sheet structure, as the β-sheet CD shows a negative peak at around 
215 nm. These results indicate that the expressed p50 has both α-helix and β-sheet 
content in its structure, which agrees with the crystal structure of p50 published by 
Chen et al (1998). These results suggest that the recombinant p50 was folded properly 
and could be used for further experiments.  In addition, Figure 4.9 shows that 
p50_S66A and p50_I142A adopt secondary structures similar to p50. This result 
suggests that p50_S66A and p50_I142A are properly folded and can be used for 
further studies. 
b.       Thermal denaturation of p50, P50_SS66A and P50_I141A mutants 
Although the CD results have shown that p50_S66A and p50_I142A are 
properly folded, we still want to confirm that the stability of these mutants is similar 
to wild type p50 through denaturation experiments. The thermal denaturation 
experiments were carried out using the method described in Section 2.4.2.  From 
Figure 4.10, it is easily seen that p50, p50_S66A and p50_I142A show similar 






C, respectively. This results 




Figure 4.9 Secondary structure of p50 and its single mutants S63A and I142A 
 
 
Figure 4.10 Thermal denaturation experiments of p50, p50_S66A and p50_I142A  
p50 (blue square), p50_S66A (open circles) and p50_I142A (open triangles) in PBS 




4.4.2.4       Which p50 mutants affect interaction of andro with p50 
In order to validate whether the docking site of andro on p50 is a real binding 
site or not, we mutated all the residues surrounding the possible binding site and 
tested how they can affect the interaction of andro with p50. From Figure 4.11, it can 
be seen that the percentage of complex formation patterns between mutants V61A, 
V115A, N139A, L140A and andro are similar with that of p50 and andro. This 
suggests that those mutants do not significantly affect the interaction between p50 and 
andro. Meanwhile, S66A/andro and I142A/andro complex formation is significantly 
reduced compared to andro/p50. This result suggests that these S66A and I142A 
mutants affect interaction of p50 protein with andro. 
From Figure 4.12 B, it is obvious that the complex formation between S66A 
and andro does not reach 100% even when the molar ratio of andro/p50 reaches 10:1. 
This result indicates that S66A reduces complex formation between p50 and andro. 
More importantly, the I142A mutants located at the center of the proposed binding 
cavity (Figure 4.12 A) did not interact with andro at all. No I142A/andro complex 
peak was observed even when the molar ratio of andro/I142A reached 10:1 (Figure 
4.12 C).  This result indicates that I142 plays a crucial role in the interaction between 
p50 and andro, and that the docking site could be the actual binding site of andro on 
p50. This binding site can be further validated by solving the structure of p50/andro 
complex. We have been trying to crystallize the p50/andro complex. So far, no 










Figure 4.11 p50 mutants affect p50/andro interaction 
V61A, V115A, N139A, L140A do not affect interaction of p50 with andro. S66 plays 
a role in complex formation between p50 and andro as the complex formation 
between p50_S66A and andro was reduced significantly compared to that between 













Figure 4.12 Docking of andro on p50 (A) and interaction of S66A (B) and I142A (C) 









4.4.3       R57 and R59 makes C62 of p50 more reactive 
The RxxRxRxxC motif is conserved in all Rel homology domains of NF-κB 
proteins. It plays an important role in DNA recognition and binding (Shen, Xu et al. 
2007). Kurmar et al (1992) have proposed that the arginine residues from 
RxxRxRxxC motif could make cysteine 62 (C62) more reactive and help it to react 
and form covalent bonds with andro (Kumar, Rabson et al. 1992). From Figure 4.13 
A, it can be seen that R54 is 24.7Å away from C62. This distance is significantly far 
away from C62  and should not have any effect on C62. However, R57 and R59 are 
very close to C62 with distances of 8.6 Å
 
and 7.3 Å, respectively. This means that R57 
and R59 could make the C62 more reactive as the SH group of C62 is nucleophilic 
and the side chains of R57 and R59 contain a NH3
+
 group. In order to validate 
Kurma’s hypothesis, we generated two single mutants R57 and R59 and compared 
their andro interaction efficacy with wild type p50.  
From Figure 4.13 B and C, it can be seen that the andro interaction efficacy of 
both R57A and R59A single mutants have been reduced significantly compared to 
wild-type p50.  R57A/andro complex formation did not reach 100% when the molar 
ratios of andro/R57 reached 10:1. Approximately 25% of R57A existed in unbound 
form when the molar ratios of andro/R57 reached 10:1. This indicates that the R57 are 
important for complex formation between p50 and andro, and that R57 is likely to 
make C62 more reactive. More interestingly, R59A/andro complex formation has 
been reduced even further, compared to R57A.  When the molar ratio of andro to 
R59A reached 10:1, R59A/andro complex formation only reached approximately 
25%. This means that R59 is likely to play a more important role than R75 in making 
C62 reactive. This result can be easily explained because R59 is 1.3 Å closer to C62 





Figure 4.13 RxxRxxRxxC motif affects p50-andro interaction 
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4.4.4       Interaction efficacy of p50 with andro and its derivatives 
There are many studies on the effect of andro and its derivatives (Pande and 
Ramos 2005). These studies only look at the physiological properties of andro and its 
derivatives on cells or the NF-κB pathway in vivo. Andro and its derivatives are 
known to target NF-κB p50. However, no study has yet looked at the specific 
interaction efficacy of andro and its derivatives with NF-κB p50. In order to 
understand the specific interaction efficacy of andro and its derivatives to p50, we 
used ESI-Qtof to identify and compare the specific interaction efficacy of andro and 
its derivatives on p50. The structure of andro and its derivatives used in this study are 
shown in Figure 4.14. 
 From Figure 4.15 D, it can be seen that andro and HWJ87 share similar levels 
of interaction efficacy with p50. The p50/HWJ87 complex is almost saturated at a 
ratio of 8:1. We did not test the interaction of HWJ120 and HWJ87 with p50 at ratios 
of 10:1, due to the limited amounts of the drug we could synthesize. The interaction 
efficacy of HWJ120 with p50 (Figure 4.15 C) is lower than andro and HWJ87. At 
molar ratios of 8:1, HWJ87/p50 complex formation only reached 50%. The 
interaction efficacy of HWJ120 is higher than that of DDAG because at ratios of 8:1 
there was still no observable interaction between DDAG. The interaction efficacy of 
DDAG is lowest among the 4 ligands as the p50/DDAG complex was observed only 
when the molar ratio reached 10:1 and it seemed to reach saturation at a ratio of 50:1 
(Figure 4.15 B). Other derivatives of andro such as neo-andro, 14-deoxy-andro, 
HWJ107, HWJ115, A140 and HWJ192 showed no interaction with p50 (Figure 4.16). 
The SEAP assay data (Table 4.2) obtained by our collaborator (A/P Fred Wong, 
Department of Pharmacology, NUS) also showed that andro, DDAG, HWJ087 and 
















 Figure 4.15 Interaction efficacy of andro (A) and its derivatives DDAG (B), HWJ120 










Figure 4.16   Interaction efficacy of 14-deoxy andro (A), neo-andro (B), HWJ 107 (C), 




Table 4.2 Summary of interaction efficacy, physiological activity and cytotoxicity 
of the various derivatives of andro 













Andro +++ +++ + 332 -18 
DDAG + + - 348 +16 
HWJ078 +++ ++ +++ 417 0 
HWJ120 + + - 232 -151 
HWJ115 - - - -  
14-Deoxy --
andro 
- - - -  
Neo-andro - - - -  
A140 - - - -  






4.4.5      Mechanism of action of andro and its derivatives 
It is important to note that when andro interacts with p50, it causes a 332 Da 
mass shift (Table 4.2), which is 18 Da lower than the molecular weight of andro (350 
Da). This can be explained by a hypothetical mechanism of action for andro proposed 
by Zhang et al (2008) and further supported by Yao et al 2012 (Figure 4.17 A). The 
α,β-unsaturated lactone moiety of andro reacts with Cys-62 of p50 through a Michael 
addition followed by dehydration of the adduct. The dehydration, which utilised the 
OH group at position 14 (the lactone ring), resulted in a molecular weight loss of 18 
Da. The interaction of HWJ087 with p50 caused a mass shift of 417 Da (Table 4.2), 
which is the same as the molecular weight of HWJ087. This experimental result could 
be because HWJ087 interacted with the SH group of Cys-62 in the same way as andro 
(Figure 4.17 B). HWJ087 does not have an OH group or any group in a position 
similar to position 14 of andro, hence there is no loss in mass shift.  
The molecular weight of DDAG is 332. However, the mass shift caused by 
DDAG/p50 interaction is 348 Da, which is 16 Da higher than the expected mass shift. 
This result could be because DDAG possesses an unstable lactone that can transform 
into furan (Figure 4.17 C). The furan can obtain an oxygen molecule and react with 
Cys-62 of P50, which would result in a 16 Da increase in molecular weight.  
The molecular weight of HWJ120 is 382 Da, yet the mass shift caused by 
HWJ120/p50 interaction is only 232 Da, 151 Da less than molecular weight of 
HWJ120. It is possible that the P50 protein loses one amino acid or a fragment during 





Figure 4.17 Hypothetical mechanisms of action for andro and its derivatives   
(A) Mechanism of action of andro proposed by Zhang et al (2008); (B) Proposed 





4.4.6       Reducing agent control of andro/p50 interaction 
4.4.6.1       Effect of reducing agents on andro/p50 interaction 
To understand the effect of reducing agents on the andro/p50 interaction, we 
used BME and DTT reducing agents. The molar ratio of andrographolide to p50 used 
for this study was 10:1. The interaction of p50-andro was tested in presence of 0, 
0.01, 0,1, 1, 10, 100 mM BME or 0, 0.001, 0.01, 0.1, 1 and 10 mM DTT.  
 
 
Figure 4.18 Effect of reducing agents on the p50-andro interaction 
Andro and p50 was incubated in the presence of different concentrations of DTT or 







From the Figure 4.18, it can be seen that reducing agents play an important 
role in the andro/p50 interaction. In the absence of reducing agents (BME or DTT), 
andro is not likely to interact with p50 as no andro/p50 complex peak was observed at 
0 concentration of BME or DTT. However, too high a concentration of reducing agent 
is also not good for the interaction as it inhibits the interaction of andro with p50. At 
100 mM of BME or 10 mM of DTT, no andro/p50 complex formation was observed.  
The optimum concentration of BME for andro/p50 interaction is 10 µM. Meanwhile, 
the optimum concentration of DTT for andro/p50 interaction is 1 µM. This result 
could be explained by the fact that the reducing power of DTT is approximately 10 
times stronger than that of BME. The result suggests that the interaction of p50 with 
andro requires reducing agents to catalyze the interaction reactions because in the 
absence of reducing agents no interaction was observed. However, a high 
concentration of BME (10mM -100 mM) and DTT (1 mM-10 mM) significantly 
diminished the interaction or stopped it completely. This result indicated that a high 
concentration of reducing agents does not favor the interaction. In conclusion, the 
optimum concentration of BME and DTT for the andro/p50 interaction are 10 µM and 
1 µM respectively.  
Xia’s study (Xia, Ye et al. 2004) showed that pre-treating cells with DTT 
prevented andro from interacting with p50. However, Xia did not mention what 
concentration of DTT was used to pretreat cells. Our result only partly agrees with 
Xia’s result because a high DTT concentration (10 mM) prevents interaction of andro 




4.4.6.2       Dissociation of the p50-andro complex by DTT 
We treated andro/p50 complex with different concentrations of DTT and 
tested whether DTT can break the covalent bond between andro and C62 of p50. 
From Figure 4.19, it can be seen that at 0 concentration of DTT, the andro/p50 
complex exists as a stable complex. When the DTT concentration increased to 2 mM, 
the andro/p50 complex started to dissociate while a significant amount of apo p50 was 
observed.  When the DTT concentration reached 5 mM, almost all the andro/p50 
complex was broken down, as shown by a major apo p50 peak and a very small 
andro/p50 complex peak.  
This is the first report mentioning that andro can be released from p50 using 
DTT. The reason DTT can break the covalent bond between andro and p50 is because 
of the interaction between andro and the SH group of C62 by Michael additions. The 
Michael reaction is potentially reversible, as mentioned in previous studies (Schmidt, 
Lyss et al. 1999; Shi and Greaney 2005).  In the Schmidt study (Figure 4.20), he 
showed that the reaction between helenanolide-type sesquiterpene lactones and GSH 
at basic pH is reversible (Schmidt, Lyss et al. 1999; Shi and Greaney 2005). Our 
result suggests that in the presence of a high concentration of DTT >= 2 mM and 
basic pH, the reversible reaction of andro with p50 could favor the reverse reaction, 
generating andro and p50 products. Moreover, the concentration of DTT used in 
andro/p50 studies should be carefully adjusted to within 0.01 – 0.1 mM. EMSA 
experiments to study the inhibition of p50/DNA binding by andro have to reduce the 




Figure 4.19 DTT can dissociate the p50-andro complex 
Andro/p50 complex was formed and confirmed by ESI-Qtof.  The andro/p50 complex 
was then treated with different concentrations of DTT from 0 mM to 100 mM. The 
results were obtained by ESI-Qtof.  
 
 




4.4.7     Interaction of p50 with SLs (parthenolide and helenalin) 
4.4.7.1       Detection of p50-parthenolide/helenalin interaction by ESI-Qtof MS 
Previous studies in vivo suggested that parthenolide, helenalin and other 
sesquiterpene lactones (SLs) interact specifically with p65 but not with p50 (Lyss, 
Knorre et al. 1998; Garcia-Pineres, Castro et al. 2001).  In this study, we wanted to 
test if parthenolide and helenalin (2 common SLs) could interact and form covalent 
bonds with p50. The interaction efficacy of parthenolide and helenalin were tested 
using similar protocol used for andro (Chapter 2). 
From Figure 4.21 A, it can be seen that parthenolide can interact with p50 and 
form a covalent bond with p50. The p50/parthenolide complex was detected by ESI-
Qtof. The complex formation between p50 and parthenolide caused a mass shift of 
approximately 248 Da, which is the same as the molecular weight of parthenolide 
(248.2). This result suggests that 1 molecule of parthenolide interacts with 1 molecule 
of p50. More interestingly, almost all the p50 formed covalent bonds with 
parthenolide when the molar ratio of parthenolide/p50 reached 2:1. This result 
suggests that the interaction efficiency of parthenolide with p50 is approximately 5 
times higher than that of andro as 100% of p50 formed complexes with andro when 
the ratio of andro/p50 reached 10:1 (Figure 4.21 B).  
From Figure 4.21 C, it can be seen that helenalin can also interact and form a 
covalent bond with p50, resulting in a p50/helenalin complex which can be detected 
by ESI-Qtof. The mass spectrum of helenalin is more complicated than parthenolide 
as there are several peaks observed near the expected p50/helenalin peak. The 
molecular weight of helenalin is 262 and we can observe that the p50/helenalin 
complex peaked with a mass shift of 262 Da from the apo p50 peak. A major peak 
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(green arrow) with a mass shift of 87 Da from the p50/helenalin complex peak was 
also observed.  
This could be the result of DMSO or BME being adducted to the p50/ 
helenalin protein. This phenomenon was also observed when p50 exists in apo form, 
which could be because BME or DMSO adducts to exposed SH group of a cysteine. 
When the ratio of helenalin/p50 reached 10/1, an extra peak with a mass increase of 
262 Da was observed, which suggests that one more molecule of helenalin interacted 
with p50. However, this peak is still lower than the helenalin/p50 complex peak, 
suggesting that the interaction of the second helenalin molecule with p50 may not be 
as efficient as for the first molecule.  
The helenalin/p50 complex reached 100% when the ratio of helenalin/p50 
reached 2:1 (Figure 21 C). This result suggests that the interaction efficiency of p50 
with helenalin is as good as that of p50 with parthenolide and approximately five 
times higher than that of p50 with andro. This new finding also suggests that both 
parthenolide and helenalin are five times more reactive towards SH groups than andro 
and could interact with many different protein targets in cells. This could at least 
partially explain why helenalin and parthenolide are far more toxic to the cells 










Figure 4.21 Interaction of parthenolide and helenalin with p50 
(A) Interaction efficacy of parthenolide with p50; (B) Interaction efficacy of andro 
with p50 used as control; (C) Interaction efficacy of andro with p50 used as control; 





4.4.7.2       Parthenolide/helenalin binds to reduced cys-62 of p50  
We have already proved that parthenolide and helenalin can interact with p50. 
However, it is still not known which residue of p50 they interact with. We 
hypothesized that parthenolide and helenalin interact with cys-62 of p50. In order to 
confirm our hypothesis, p50_C62A mutant was used to interact with parthenolide and 
helenalin at the ratio of 20 parthenolide or helenalin to 1 p50_C62A. From Figure 
4.22 A, it can be seen that parthenolide does not interact with p50_C62A. This result 
indicates that parthenolide interacts with C62 of p50. When the C62 was mutated to 
A62, no interaction between parthenolide and p50 was observed. Similarly, from 
Figure 4.22 B, it can be seen that helenalin does not interact with p50_C62A. This 
result indicates that helenalin interacts with C62 of p50. When the C62 was mutated 




















Figure 4.22 Interaction of parthenolide and helenaline with C62 of p50 
(A) Parthenolide could not interact with p50 when the C62 was mutated to A, indicating 
that parthenolide selectively interacted with C62. (B) Helenalin could not interact with 





4.4.7.3       Inhibition of p50/κB oligonucleotide binding by parthenolide 
We have already proven that parthenolide can interact with p50 by forming a 
covalent bond with C62. We want to examine whether the interaction of parthenolide 
with p50 can prevent p50 from binding to κB site, thus inhibiting p50 function. The 
inhibition of p50/κB DNA binding by parthenolide was analyzed using the EMSA 
method as described in Section 2.6.3.  
From Figure 4.23, it can be seen that p50 can specifically interact with κB 
DNA (lane 3) as pretreated p50 with unlabeled κB DNA prevented p50 from binding 
to labeled κB DNA (lane 2). When parthenolide interacted with p50, it prevented p50 
from binding to κB DNA (lane 3) resulting in only the unbound labeled κB DNA 
being observed (lane 3).  This result confirmed that when parthenolide interacts with 
p50, it prevents p50 from binding to κB DNA. 
 




 4.4.8       Andro interacts weakly with p65 
As parthenolide can intereact with p65 and p50, we also want to validate 
whether andro can only interact with p50 or whether it can also interact with p65. The 
N-terminal domain (aa 19-191) of the p65 Rel homology domain (Np65) was used to 
interact with andro. The interaction was analyzed by ESI-Qtof.  
From Figure 4.24, it can be seen that andro can only interact very weakly with 
p65. At molar ratios of 50 andro to 1 p65, only 50% of p65 forms complexes with 
andro. This result indicates that andro selectively interacts with C62 of p50 and does 
not favor the interaction with p65. This result also partially explains why andro is 
significantly less toxic to cells compared to parthenolide or helenalin as well as why 
parthenolide can kill cancer cells better than andro.  
 
Figure 4.24 Weak interaction of andro with p65 
 
4.4.9   Interaction of p65 with parthenolide and henelalin 
4.4.9.1       Interaction of parthenolide with p65 
N-terminal domains (aa 19-191) of p65 Rel homology domain (p65) were 
purchased from Genscript USA Inc. They were subcloned into pET-M expression 
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vectors.  p65 mutants (C38S, 120S) were generated by method described in Section 
2.2.8. All constructs were subsequently transformed into E. coli BL21(DE3) cells for 
protein expression described in Chapter 2.  
The interaction efficiency of parthenolide with p65 was analyzed using ESI-
Qtof. From Figure 4.25, it can be seen that at molar ratios of 2:1 (parthenolide/p65), 
there are 3 major peaks (peak 1, peak 2 and peak 3) which correspond to apo p65, p65 
+ 1 parthenolide and p65 + 2 parthenolide.  The mass shift between peak 1 and peak 2 
is equal to the mass shift between peak 2 and peak 3. Both are equal to the molecular 
weight of parthenolide (248 Da). This result suggests that there are at least 2 
interacting targets on p65 that parthenolide can interact with and form covalent bonds. 
When the molar ratios of parthenolide to p65 reached 20:1, a major peak was 
observed at the mass corresponding to p65+2 parthenolide. This result suggested that 
the bond between parthenolide and both binding sites could saturate when the molar 

















4.4.9.2       Interaction of Parthenolide with C38 and C120 of p65 
We have found that there are two parthenolide targets on p65 and previous 
studies have also proposed that SLs could form covalent bonds with C38 and C120 of 
p65. Thus, we want to experimentally prove that parthenolide can interact with C38 
and C120 of p65. Single mutants p65_C38S and p65_C120S were generated using 
method described in Section 2.2.8. These two mutants were used to test their 
interaction efficacy with parthenolide. From Figure 4.26 A, it can be seen that 
parthenolide can interact with C120S of p65 and the interaction reaches 100% 
efficacy when the molar ratios of parthenolide to p65 reaches 4:1. This interaction 
efficacy is slightly lower than that of parthenolide to p50 as the interaction of 
parthenolide to p50 reaches 100% efficacy when the molar ratio of parthenolide to 
p50 reaches 2:1.  
We also observed that the mass shift between p65_C38S and 
p65_C38S/nomo-parthenolide is 248 Da, which is the same as the molecular weight 
of parthenolide. However, when parthenolide interacts with p65_C120S, the mass 
shift observed at molar ratios of 4:1 or 8:1 (Figure 4.26 B) was approximately 496, 
which is double the molecular weight of a parthenolide molecule, indicating that 2 
parthenolide molecules are still able to bind to p65_C120S. This result could be 
because one parthenolide molecule interacts with C38 while another parthenolide 
molecule interacts with an NH2 group in a p65 protein. The possibility that 
parthenolide could interact with an NH2 group from a p65 protein is likely to happen. 
A similar study by Yao and coworkers showed that both the SH and NH2 moiety of 
GSH could interact with andro, utilising a Michael addition mechanism. They were 
also assumed to have a similar mechanism of interaction with C62 of p50 as 
135 
 
parthenolide (Yao, Li et al. 2012). In order to confirm that parthenolide mainly 
interacts with C38 or C120 of p65, double mutant p65_C38S_C120S needs to be 
generated and used to confirm the binding sites of parthenolides. 
The interaction efficacy of parthenolide with p65_C120S is low compared to 
that of parthenolide and P56_C120S. At molar ratios of 8:1, the complex formation 
between p65 and parthenolide is still below 50%. Meanwhile the complex formation 
between parthenolide and p65_C38S reaches 100% when the ratio of parthenolide to 
p65_C38S reaches 4:1. This result suggests that C120 may be more reactive than C38 
in interacting with parthenolide.  
 
 
     Figure 4.26 Interaction of parthenolide with p65_C38S (A) and p65_C120S (B) 
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4.4.9.3       Interaction of helenalin with p65 
The interaction efficiency of helenalin to p65 was analyzed using ESI-Qtof 
(Section 2.6.2). From Figure 4.27, it can be seen that at molar ratios of 4:1 (helenalin 
to p65), there is a major peak corresponding to p65 + 1 helenalin.  The mass shift 
between p65 + 1 helenalin and apo p65 peak is equal to the molecular weight of 
helenalin (262 Da). This result suggests that helenalin interacts with p65 and the 
interaction reaches 100% when the molar ratio of helenalin to p65 reaches 4:1. This 
interaction efficacy is similar to the interaction efficacy of parthenolide with C120 of 
p65. 
 




4.4.9.4       Docking of helenalin on 65 
In order to identify the possible binding site of helenalin to p65 and study its 
mechanism of action, the p65 structure from the crystal structure of NF-κB p50/p65 
(PDB ID: 1vkx) was used for docking with andro. The docking was done using the 
program Autodock 4.0 (Morris, Goodsell et al. 1998), as explained in Section 2.6.1. 
The obtained results (Figure 4.28) shows that helenalin was docked in a cavity 
surrounded by C38, C120, K37, K122, D125, V121, Q119, E89, R133 and K128. In 
order to confirm that this cavity is the possible binding site of helenalin, single 
mutants C38, C120, K37, K122, D125, V121, Q119, E89, R133 and K128 need to be 
generated in the future.  These mutants can then be used to test whether they are able 
to affect the binding of helenalin to p65.   
 
Figure 4.28 Docking of helenalin to 65 
 
4.5    CONCLUSION 
NF-κB controls over 500 genes, which are involved in many cellular processes 
such as cellular transformation, survival, proliferation, invasion, angiogenesis, 
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metastasis, and immune responses. Constitutive activation of NF-κB has been linked 
to numerous human diseases including atopic dermatitis. Therefore, the inhibition of 
the NF-κB pathway, especially the area of NF-κB/DNA binding inhibition, is 
considered a hot target for drug discovery (Pande, Sharma et al. 2003; Pande and 
Ramos 2005). Andro, the most active compound isolated from a Chinese herbal plant 
named Andrographis paniculata, can form covalent bonds with Cys-62 of p50 and 
inhibit NF-κB activation. Although andro has shown therapeutic potential for 
treatment of inflammatory diseases such as atopic dermatitis and asthma, it has 
relatively high toxicity, indicating that more work needs to been done in developing  
andro and its derivatives as potent NF-κB inhibitors with minimal side effects (Uwe 
2008). 
In this study, we have identified possible binding sites of andro with p50 using 
docking and mutation combined with andro/p50 complex identification using ESI-
Qtof. This result suggests that andro needs a binding cavity so that it can interact with 
Cys-62 of p50 as it weakly interacts with Cys-38 of p65 even though Cys-38 of p65 
has similar reactivity. We also experimentally proved that the R57 and R59 of 
R54xxR57xR59xxC motif could make Cys-62 of p50 more reactive, which helps to 
explain why andro only interacts with Cys-62 of p50 but not with other exposed 
cysteine in cells. 
In this study, the interaction efficacy of p50 with andro and its derivatives are 
characterized by the ESI-Qtof method. We identified that andro and its derivative 
HWJ078 have the highest levels of interaction efficacy with Cys-62 of p50. DDAG 
has low interaction efficacy as it only interacts with all of the p50 when the molar 
ratio of DDAG/p50 reaches 50:1. This method is able to help in comparing the 
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interaction efficacy of different inhibitors with p50 as well as explaining the 
mechanism of interaction of inhibitors. Andro formed a covalent bond with Cys-62 of 
p50 and lost 1 water molecule (18 Da). This result agrees with previous results (Xia, 
Ye et al. 2004; Zhang, Chan et al. 2008; Yao, Li et al. 2012).  
Interestingly, we have discovered for the first time that parthenolide can 
interact with p50 by forming a covalent bond with Cys-62. The interaction efficacy of 
parthenolide with p50 is much higher than that of parthenolide with p65 and 5x higher 
than that of andro with p50. The interaction of parthenolide with p50 inhibits 
p50/DNA binding. This result also suggests that parthenolide can interact with a great 
number of other exposed cysteine residues of many other cellular proteins and make 
them very cytotoxic. These results suggest that parthenolide can be a good lead 
compound to develop inhibitors, which can inhibit both p50 and p65.  
In this study, we also confirmed that parthenolide could interact with both 
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CHAPTER 5.    FUTURE DIRECTIONS 
5.1    Dermcidin – the human antimicrobial peptide 
 The 3D structure of DCD1L obtained in this study supports Schittek’s 
hypothesis that the N-terminus of DCD1L inserts into bacterial membrane 
while the C-terminal is exposed outside and may bind to the surface of the 
membrane. In order to further confirm this model, a complex of DCD1L with 
POPG vesicles can be exchanged with D2O, so that the exposed part of 
DCD1L can be detected using hydrogen-deuterium exchange (HDX) mass 
spectrometry method. 
 The C-terminus (Glu-30 to Leu-48) of DCD1L is not likely to bind to POPG 
vesicles. Mutation of critical amino acid residues, especially charged residues, 
at the C-terminus may help it bind better to the bacterial membrane as well as 
increase our understanding of the role of the C-terminus. 
5.2    Nuclear factor kappa B p50 and p65 
 We have shown the possible interaction site of andro on p50 using docking 
and mutation; however, to further confirm this model, the crystal structure of 
andro/p50 complex should be obtained. 
 We have successfully used ESI-Qtof to identify the interaction affinity of 
parthenolide and helenalin with p50 and p65. This method can be applied to 
compare the interaction affinity of p50 and p65 inhibitors, which also form 
covalent modifications with critical cysteine residues.  
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 We have discovered parthenolide can interact with p50 by forming a covalent 
bond with Cys-62. This result also suggests that parthenolide may interact 
with many other exposed cysteine residues of many other cellular proteins. 
Therefore, the identification of all protein targets that parthenolide can interact 
with remains to be studied.  
 As parthenolide can interact with p50 and p65, it is interesting to use 
parthenolide as a lead compound to develop inhibitors, which can inhibit both 
p50 and p65 with minimal side effects. 
 The docking of helenalin on 65 suggests that helenalin might bind to p65 at a 
cavity surrounded by C38, C120, K37, K122, D125, V122, Q119, E89, R133 
and K128. Single mutants C38, C120, K37, K122, D125, V122, Q119, E89, 
R133 and K128 need to be generated in the future to test whether they could 
affect the binding of helenalin to p65.   
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Recipe  for 4 SDS-PAGE gels with dimension (0.75mm x 8cm  x 10cm) 







Resolving Buffer 3.5  ml - 
 
Stacking Buffer - 
 
1.5 ml 
10% SDS 140 μl 60 μl 




84 μl 60 μl 
 
TEMED 8.4 μl 6 μl 
 
 
Shown below are the formulas used for preparing the stock solutions necessary for the 
SDS-PAGE gels; 
 
1.    Acrylamide solution (30%, 0.8 % Bis) 
2.    Resolving gel buffer: 1.5 M Tris, pH 8.8 
 For 500 ml, 90.75 g of Tris adjust to pH 8.8 with HCl 
 
3.    Stacking gel buffer: 0.5 M Tris, pH 6.8 
 For 500 ml, 30.25 g Tris, adjust to pH 6.8 with HCl 
 
4.    10% Ammonium persulphate: 1 g Ammonium persulphate in 10 ml water 
5.    10X Tank buffer: for 1 liters 
 
 30 g Tris base 
 144g Glycine 
 100 ml 10% SDS solution 
 Add water to 1 liters 
 
6.    2X SDS gel sample buffer: for 50 ml 
 5 ml   Glycerol 
 6.25 ml  0.5 M Tris pH 6.8 
 12.5 ml  10% SDS 
 2.5 ml   β-mercaptoethanol 
 0.01 g   Bromophenol blue 
 Add water to 50 ml 
 
7.    Stain stock: 1% Coomassie Brilliant Blue G (Stir and filter) 
8.    Destaining solution: for 2 liters 
 
 140 ml  Acetic acid 
 100 ml  Methanol 
 Add water to 2 liters 
